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Overview 
This three-part thesis focuses on psychological therapy for personality 
disorders (PDs) and factors that influence both treatment completion and outcome. 
 Part one is a literature review investigating documented mechanisms of 
change in the cognitive behavioural therapy (CBT) and dialectical behavioural 
therapy (DBT) treatment for borderline personality disorder (BPD) in current 
research. Although much research has focussed on improving treatment outcomes 
for BPD, there is very little research investigating the proposed changes by which 
these outcomes might occur. Three distinct categories of mechanism of change 
were found to be consistent across the literature examined. These categories are 
discussed in detail along with implications for future research and clinical practice.  
 Part two presents a longitudinal empirical study of factors which affect 
treatment completion and treatment outcome in the CBT or DBT treatment of PD. 
Data spanning a six year period was collected and analysed for 231 patients. 
Results showed that therapist expertise was the only variable examined associated 
with treatment completion: more experienced therapists retained their patients in 
treatment for longer than less experienced therapists. Therapeutic dose (number of 
sessions attended), therapist expertise and substance misuse all predicted changes 
in risk outcome (deliberate self-harm, suicide attempts) and in number of PD 
diagnoses following treatment. Only therapeutic dose predicted change in other 
clinical diagnoses following treatment. Implications and strength of these findings 
are discussed in relation to problems with incomplete data, statistical analyses and 
non-representative sampling issues. 
 Part three is a critical appraisal of the entire research process reflecting upon 
its challenges and successes. This section also includes a commentary on the field 
of PD research in general, and considers issues pertinent to future research. 
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Abstract 
Aims: Little is known about the ‘active ingredients’ of psychological therapy for 
Borderline Personality Disorder (BPD) despite a growing evidence base 
documenting its clinical effectiveness. This review analyses studies investigating 
potential mechanisms underlying therapeutic change in Cognitive Behavioural 
Therapy (CBT) and Dialectical Behaviour Therapy (DBT) for BPD. 
Method: A thorough search of the PsychInfo, CINAHL Plus, PubMed, MEDLINE 
and EMBASE databases revealed empirical research on the potential mechanisms 
of change. 
Results: One hundred and four references were identified and 34 abstracts 
reviewed. After a full text screen of the most relevant studies, nine met inclusion 
criteria. Seven examined DBT and two CBT. Mechanisms of change identified 
broadly fell into three categories: emotion regulation/self-control, skills use and 
therapeutic alliance/investment in treatment. Outcomes measured included general 
clinical syndromes (anxiety/depression) and BPD-specific symptoms (self-
harm/suicidality, impulsivity, substance misuse, anger).    
Conclusion: Further empirically-robust research is required to test hypotheses 
about the influence of the proposed mechanisms on therapeutic change in 
treatments for BPD.  
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Introduction 
Personality Disorder (PD) is a condition previously defined on Axis II of the 
Diagnostic and Statistical Manual of Mental Disorders-IV-TR (DSM-IV-TR; American 
Psychiatric Association, 2000) as, “an enduring pattern of inner experience and 
behaviour that deviates markedly from the expectations of the individual’s culture, is 
pervasive and inflexible, has an onset in adolescence or early adulthood, is stable 
over time, and leads to distress or impairment” (p. 685). However, although the 
newly published fifth edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5; American Psychiatric Association, 2013) uses the same 
definition of PD, it no longer makes a distinction between Axis I (clinical syndromes 
such as anxiety and depression) and Axis II (entrenched, pervasive patterns of 
behaviour reflecting an individual’s inherent personality characteristics), instead 
combining the first three Axes outlined in previous editions into one Axis 
incorporating all mental and other medical diagnoses. It is thought that this change 
will benefit both clinical practice and scientific research (American Psychiatric 
Association, 2013).  
The ten distinct types of PD remain in DSM-5 as they were in DSM-V-TR, 
dividing into three clusters based on their descriptive similarities. The current review, 
however, will focus solely on Borderline Personality Disorder (BPD), described by 
Bateman and Fonagy (2004) as, “a complex and serious mental disorder that is 
characterised by a pervasive pattern of difficulties with emotion regulation and 
impulse control and instability both in relationships and self-image” (p.1).  BPD is 
arguably one of the more common personality disorders seen in PD services (Coid, 
Yang, Tyrer, Roberts & Ullrich, 2006; de Ruiter & Greeven, 2000) and is highly 
studied as it is associated with high rates of suicide, self-harm, violence, and 
drug/alcohol addiction (American Psychiatric Association, 2013), therefore resulting 
in a high level of service usage (Bender et al., 2001; Comtois et al., 2003) and high 
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mortality rates (American Psychiatric Association, 2001). Many research efforts 
have therefore attempted to identify effective treatment for the condition.  
One of the obstacles influencing effective treatment for BPD is the problem 
of treatment adherence. Several characteristics of the disorder (e.g. impulsivity, 
recurrent suicidal behaviour) unfortunately lend themselves to early disengagement 
from treatment and difficulty committing to and engaging with the therapeutic 
process. 
BPD is characterised by difficulties in establishing trusting and collaborative 
interpersonal relationships and, “frantic efforts to avoid real or imagined 
abandonment” (American Psychiatric Association, 2013) which naturally extend to 
difficulties in the therapeutic relationship, thus presenting further challenges for 
treatment.  
However, contrary to previous opinion which held that due to its entrenched 
roots in childhood personality development, PD was largely untreatable, there is 
now evidence to suggest that BPD and other PDs are not immutable and are likely 
to change over time with successful psychological treatment (e.g. Bateman & 
Fonagy, 2000; Bateman & Fonagy, 2004; Bateman & Fonagy, 2008; Bloom, 
Woodward, Susmaras & Pantalone, 2012; Kliem, Kröger & Kosfelder, 2010; Panos, 
Jackson, Hasan & Panos, 2013).   
Many research efforts have attempted to ascertain the efficacy of different 
psychotherapies used for the treatment of BPD including Dialectical Behaviour 
Therapy (DBT) for women which is currently the only treatment recommended for 
BPD by the National Institute for Clinical Excellence (NICE, 2009; Stoffers et al., 
2012). NICE does, however, suggest that should the evidence base be produced, 
future revisions may advocate the treatment of BPD using Cognitive Behaviour 
Therapy (CBT; Beck, Freeman & Davis, 2004), Mentalization Based Therapy (MBT; 
Bateman & Fonagy, 2008; Bateman & Fonagy, 2004) and Schema Therapy (Kellogg 
& Young, 2006). DBT could be described as a third-wave CBT therapy and has a 
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growing large and robust evidence base (e.g. Bloom et al., 2012; Feigenbaum et al., 
2011; Feigenbaum, 2007; Kliem et al., 2010; Linehan et al., 2006; Panos et al., 
2013). Likewise, strong bodies of empirical evidence reliably document the 
effectiveness of both generic CBT (Butler, Chapman, Forman and Beck, 2006) and 
CBT specifically for BPD (Davidson et al., 2006). The current review will therefore 
focus solely on the CBT and DBT treatment of BPD.  
CBT uses traditional cognitive and behavioural techniques to teach patients 
to identify dysfunctional thoughts and core beliefs and to learn to challenge and 
modify them. CBT for BPD focuses particularly on developing functional new core 
beliefs. The therapeutic relationship is seen as a vital means for exploring the 
patient’s style of relating to others and for fostering more adaptive interactions in the 
future. More specifically, Arntz (1994) describes CBT for BPD as consisting of five 
stages: i) construction of a working relationship, ii) symptom-management, iii) 
correction of thinking errors, iv) emotional processing and cognitive re-evaluation of 
childhood trauma and schema changes, and v) termination. Davidson et al. (2006) 
conducted a large randomised controlled trial (RCT) of individual CBT for BPD 
verses treatment as usual (TAU) which found that CBT was roughly equivalent to 
TAU on outcomes of suicidal behaviour, presentation to A&E services and number 
of inpatient psychiatric days over the two year study period. However, CBT was 
found to be superior to TAU in reducing the number of suicidal acts and decreasing 
dysfunctional beliefs, state anxiety, and psychiatric symptom distress. Leichsenring 
and Leibing (2003) reported significant effects for more specific measures of PD 
pathology for CBT over that of psychodynamic therapy for PD.   
Developed by Linehan (1993), DBT uses strategies from CBT to aid the 
regulation of emotions as well as teaching distress tolerance and using third wave 
approaches to promote awareness and acceptance. Linehan et al. (2006) concluded 
that DBT was superior in reducing suicide attempts in the treatment of BPD when 
compared to a community treatment that was specifically developed for the study 
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and delivered by experts. Brazier et al. (2006) conducted a systematic review 
summarising the available evidence on the clinical effectiveness of psychological 
therapies for BPD, concluding that DBT was equal to or superior to other treatments 
with regards to clinical effectiveness. A recent meta-analysis and systematic review 
by Panos et al. (2013) investigating the efficacy of DBT for BPD revealed a net 
benefit in favour of DBT when combining effect measures for suicide and 
parasuicidal (self-harm) behaviour. Regarding DBT in inpatients with BPD, Bloom et 
al. (2012) systematically reviewed 11 studies reporting pre- and post-treatment 
symptoms in the DBT treatment of BPD finding reductions in suicidal ideation, self-
injurious behaviours, and symptoms of depression and anxiety in most studies. 
Importantly, follow-up data mostly revealed maintenance of symptom reduction 
between one and 21 months post-treatment. 
Despite the plethora of empirical data documenting the efficacy of both CBT 
and DBT for BPD, most research to date has focused solely on outcome data with 
relatively few studies identifying the reasons why treatments are successful, and 
what might be the specific active processes or ‘mechanisms of change’ through 
which improvements occur. Clarkin and Levy (2006) highlight the difference 
between the vast number of outcome studies and the relatively few studies of 
mechanisms of change clarifying that, “the question of the mechanisms of change in 
psychotherapy seeks to learn how a particular therapy works, not what is the 
outcome of the treatment per se” (p. 405). Elliott (2010) refers to this research as 
‘change process research’ describing it as, “a necessary complement to randomised 
clinical trials and other forms of efficacy research” (p. 123). Kazdin (2007) discusses 
the lack of evidenced explanation for why, in even the most rigorously researched 
psychotherapeutic interventions, researchers lack insight into the mechanisms 
through which these treatments result in successful outcomes. He advises that 
future investigations should strive towards this as the next step in psychotherapy 
research.  
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Identifying the specific mechanisms of change by which BPD patients 
improve through treatment has vast implications for the future of psychological 
therapy for BPD. Pre-assessment, this data could allow clinicians to predict which 
patients are more likely to do well from receiving CBT or DBT treatment and which 
patients may do better in receipt of alternative therapies.  
This review therefore analyses the empirical literature to date, aiming to 
isolate and identify specific mechanisms of change in both the CBT and DBT 
treatment of BPD. In particular, the review aims to answer the question, what are the 
specific mechanisms of change in the CBT and DBT treatment for BPD?  
 
Method 
Searches of paper titles, abstracts and full text content were performed in 
July and August 2012 and then repeated in February 2014 (see below), in the 
PsychInfo, CINAHL Plus, PubMed, MEDLINE and EMBASE databases. The search 
terms used were: a) “mechanism* change borderline personality disorder”, b) 
“mechanism* change” and “borderline personality disorder”, c) “mechanism* 
change” and “BPD”, d) “mechanism* change” and “borderline personality disorder” 
and “treatment” and e) “borderline personality disorder” and “therapeutic change.” 
Studies included in the review involved i) participants who met diagnostic 
criteria for BPD, ii) who had received either CBT or DBT treatment for their BPD, iii) 
were either outpatients or partially hospitalised when they received their treatment 
(due to the limited number of manualised studies of inpatients with BPD), iv) were 
treated as part of full text peer-reviewed studies published in English since 1990 (as 
this was the earliest that the literature began to report CBT and DBT treatment of 
BPD), and v) were adults (aged over 18) at the time of their BPD treatment (as there 
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is a limited research presence investigating emerging BPD in adolescents). The 
review excluded: i) single case studies of BPD treatment. 
An initial search of the CINAHL Plus and MEDLINE databases combined 
using search term a) with the limits ‘January 1990 to present’ yielded 8479 hits. The 
same search using search term b) yielded only six results. Re-running this search 
and additionally ticking the ‘find all my search terms’ box returned two additional 
results. All eight were added to a shortlist.  Running the same search again with 
search term c) produced 13 hits, four of which were relevant but had already been 
returned in the previous two searches. It was clear from the titles of the remaining 
nine papers that they related to medical disorders not BPD. Search term d) also did 
not return any hits not previously revealed in earlier searches. 
Searching the PubMed database with search term a) with no date limits 
revealed nine hits which were added to the shortlist. Search term b) revealed the 
same nine hits. Search term c) returned 14 hits; however, as previously, it was 
evident from their titles that ten of these related to specific medical conditions and 
not to BPD. The four relevant hits had already been revealed previously in searches 
using search terms a) and b). Search term d) did not return any hits not previously 
revealed in earlier searches. 
Searching the PsychInfo database using search term a) with no limits 
returned 5684 hits. The search was therefore repeated with the addition of the 
following limits: ‘full text only’, ‘peer-reviewed only’, ‘1990-2012 only’, ‘English 
language only’, ‘adulthood only (aged 18 and up)’. This search returned only 19 hits. 
Three were added to the shortlist. The remaining 16 were not relevant as it was 
evident from their titles that they were purely pharmacological or medical studies. 
Search terms b) and c) did not reveal any additional results. Search term d) was 
conducted with the additional limits of ‘human only’ and ‘outpatients only.’ This 
search returned 30 hits, 11 of which were added to the shortlist. The 19 not added to 
the shortlist bore titles which related to disorders other than BPD or were clearly 
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medical, not psychological in nature. Running all four search terms in the EMBASE 
database yielded no results not already revealed in previous searches.  
The fifth search term e) was added (“borderline personality disorder” and 
“therapeutic change”). Running this search term with no limits in CINHAL Plus, 
PubMed and PsychInfo did not reveal any results not previously achieved. Running 
this search term with no limits in the MEDLINE database revealed eight hits, five of 
which were relevant and added to the shortlist and three of which were excluded as 
irrelevant on the basis of their titles alone. The same search conducted in the 
EMBASE database with no limits revealed five hits, all of which were relevant but all 
of which had already been returned in the MEDLINE search and had therefore 
already been added to the shortlist.    
Exclusion of non-relevant papers from a title screen only reduced 95 papers 
to 36 papers. Nine were removed as they were duplicates of papers already in the 
shortlist but not previously removed at earlier screening. Twenty seven papers 
remained and the full abstracts were reviewed for all 27. Following review of these 
abstracts, 14 papers were removed as they did not meet inclusion criteria. The most 
common two reasons for rejection at this stage were because papers either focused 
on treatments for BPD other than CBT or DBT or because they were literature 
reviews rather than empirical studies. This left 13 papers for which the full texts and 
reference lists were fully reviewed. No additional relevant studies not already 
included were found among reference lists. Of these 13 papers, three were 
excluded, one because it was comparing DBT across group and individual delivery 
and did not consider mechanisms of change in any detail, one because it became 
apparent that it was only concerned with MBT and one because it investigated only 
psychodynamic psychotherapy. A further two papers were initially thought to be 
appropriate for inclusion in the review but upon detailed review of the full texts were 
ultimately excluded as they could not provide any information on mechanisms of 
change in either CBT or DBT treatment of BPD. The first study (Yen, Johnson, 
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Costello & Simpson, 2009) set out to identify mechanisms of change in DBT for BPD 
among a sample of 50 patients but concluded that BPD is not homogenous and it is 
therefore impossible to identify any common mechanisms of change. A second 
study (Gratz, Lacroce & Gunderson, 2006) crucially failed to separate out the effects 
and potential benefits of several different treatment approaches, combining three 
different psychological therapies (DBT, CBT and psychodynamic psychotherapy) 
alongside both psychoeducation and psychiatric medication. This study additionally 
joined partial hospitalisation with intensive outpatient treatment, limiting the 
possibility for investigating mechanisms of change in outpatient CBT and DBT in 
isolation.  
On review of one excluded paper (Barnicot et al., 2012; a systematic review 
of factors predicting outcome across all psychotherapeutic treatments for BPD), five 
further studies which empirically tested factors affecting treatment outcome were 
identified within the reference list. Of these five, four did not meet inclusion criteria 
for the current review, as factors considered were mainly pre-treatment static 
characteristics as opposed to dynamic mechanisms of change that could 
conceivably be altered during the course of therapeutic treatment. One further paper 
did meet inclusion criteria, however, taking the total number of papers to nine.  
As a final check of the literature following a period of inactivity, in February 
2014 identical searches were re-run in all five databases using search terms a)-e) 
and nine further references were revealed. With the exception of the PubMed 
database there were no changes to the initial search results. Searching term a) in 
the PubMed database revealed one additional paper which was then excluded 
following abstract screen as it reported results from an emotion regulation group, not 
CBT or DBT. Searching term e) in the PubMed database exposed a further relevant 
paper, ultimately excluded following a full text screen as it also did not investigate 
CBT or DBT. Seeking out the full text of this paper, however, revealed a special 
(2013) Personality Disorder edition of the journal Psychotherapy Research. After an 
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initial title screen of all seven published papers, five were found to be relevant. After 
screening full texts all but one were excluded for non-CBT or DBT treatment, or for 
not including patients with a diagnosis of BPD. On full review of the paper which 
initially appeared to meet inclusion criteria (McMain et al., 2013) it became clear that 
this study would be of limited use for the current review as although it focussed on 
changes in emotion processes in DBT for, and general psychiatric management of, 
BPD, a large proportion of data was missing limiting generalisability. Additionally, 
the number of participants in each treatment group was unbalanced which together 
with the relatively small sample size meant that power was not sufficient to test for 
differences between the two treatment types and therefore the mechanisms of 
change functioning in DBT could not be determined.  
Following the 2014 search the total number of references screened rose to 
104, with 34 abstracts and 19 full texts ultimately reviewed. The final total of papers 
included in the review remained at nine. See Figure 1 for flow chart illustrating the 
database search process. 
 
Results 
Limiting the results as described yielded a total of 104 studies for review. 
After screening titles, abstracts and full texts, nine studies met criteria for inclusion in 
the final review. A list of these studies and their relevant features is provided in 
Table 1.  
Each study is described in some detail under one of three broad categories 
of mechanism of change: i) emotion regulation and self-control, ii) skills use and iii) 
therapeutic alliance and investment in treatment. A critical evaluation of each study’s 
methodology and findings are included, measured against a well-known critical 
appraisal checklist (Downs & Black, 1998, see Appendix A) which assesses the 
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Figure 1: Flow chart of review database 
 
Electronic database 
search results 
N = 104 
Excluded following 
electronic title screen 
N = 61 
Abstracts screened 
N = 34 
Excluded 
following 
abstract screen 
N = 15 
Excluded due to replication 
N = 9 
Full texts screened 
N = 19 
Excluded 
following full text 
screen 
N = 11 
Papers included in 
final review  
N = 9 
 
 
 
Additional papers 
identified in full text 
screen 
N = 1 
N = 8 
Table 1  
Papers included in the review 
 
Paper       Primary therapeutic   Control group     Sample               Sample                         Mechanism(s) of change                    Main findings 
                orientation                                      size              demographics 
 
Axelrod et al. (2011)           DBT                    No                   27            Women with BPD and            Improvements in                   Improved emotion regulation 
                                 substance dependence         emotion regulation                 can account for increased      
                         behavioural control 
 
Bedics et al. (2012)      DBT                   Yes                 101           Women with BPD                    Personality factors and        DBT patients reported greater                                          
                                                                                                                                                              intrapsychic change             self-affirmation, protection,                 
                                   love and less self-attack 
 
Davenport et al. (2010)      DBT                   Yes                  17            Men and women with              Personality and self-            Pre-treatment participants    
                                                                                                              primary diagnosis of BPD        control                       lower on self-control,   
                                                                                       conscientiousness and    
                                                                                       agreeableness than post- 
                        treatment participants 
 
Gibbons et al. (2009)          CBT                    Yes                  34           Men and women with               Self-understanding              Change in compensatory  
                                                                                                              primary diagnosis of BPD        and compensatory               skills observed in BPD  
               skills                                     group 
  
Lenzenwenger et al. (2012)     DBT                   Yes                 58       Men and women meeting         Anger and aggression,        No significant difference in  
    criteria for BPD, aged               global functioning and         changes on proposed  
    18-50                                        social adjustment,               mechanisms of change 
                                                     affective dyscontrol              between treatment types. 
 
Neacsiu et al. (2010)           DBT                   Yes                108          63 recurrently suicidal               Increasing use of DBT         DBT skills use mediated  
              women with BPD/45 women     skills                                    decrease in suicide                                         
             with BPD                                                                                attempts and depression 
 
Perroud et al. (2012)           DBT                    No                     52        Men and women with suicidal   Mindfulness and                  Increases in skill of       
                                                                                                             /para-suicidal behaviour            acceptance                        accepting without judgement
                      and BPD                                                                                correlated with improvement                       
         in BPD symptoms 
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Turner (2000)                      DBT               Yes                    24            Men and women with BPD         Quality of therapeutic          DBT group improved            
                                     alliance                                more than controls on 
                                  most outcomes 
 
Wenzel et al. (2006)           CBT                No                     27     Men and women with BPD          Belief change,                     Positivity to treatment 
                                                                                                                                                                reduction in                         correlated with  
                                                                                                                                                                hopelessness,                    improvement in BPD 
                                                        improvement in           diagnostic criteria 
                                                        attitude towards     
                                                        treatment 
 
 
 
 
 
 
 
 
 
methodological quality of both randomised and non-randomised studies of 
healthcare interventions. This 27 item checklist assigns a numerical score out of a 
maximum of 32. Due to difficulty in ascertaining reliable scores for the final item 
concerning power analyses (which awards up to five points), this item has instead 
been scored either ‘zero’ (no power calculation completed or power not met) or ‘one’ 
(power calculation completed, and met). Therefore, a maximum score of 28 is 
possible (item five only is worth up to two points). A summary of each study’s 
performance against the checklist can be found in Table 2 (DBT) or Table 3 (CBT).  
Table 2:  
Checklist appraisal of DBT studies according to Downs & Black (1998) 
 
Paper                   Strong points according         Weak points according          Total score 
                        to checklist                        to checklist                         (/28) 
          
 
Axelrod et al. (2011)            Outcome measures,  Attrition (44.4% did not       16 
         reporting, sampling  complete treatment), non- 
                        randomisation, lacked control 
 
Bedics et al. (2012)       Randomisation  Unable to determine treatment         21 
       compliance 
 
Davenport et al. (2010)       Control comparison               Non-randomisation of participants   16 
         group           to control/treatment condition 
 
Lenzenwenger et al. (2012) Randomisation               Non-blinding of participants              20 
 
Neacsiu et al. (2010)            Randomisation, control  Non-blinding of participants              26       
     group, blind assessors    
 
Perroud et al. (2012)     Outcome measures,             Lack of control group                        19 
      sampling      
 
Turner (2000)     Randomisation, blind Lack of information about       21 
     independent assessors         non-completers  
 
 
 
Table 3 
Checklist appraisal of CBT studies according to Downs & Black (1998) 
              
 
Paper                    Strong points according           Weak points according        Total score 
                        to checklist                        to checklist                         (/28) 
          
Gibbons et al. (2009)       Randomisation, large              Non-blinding of participants           20 
         sample, several comparison    
         groups      
 
Wenzel et al. (2006)            Management of data of            Lack of control group                    19  
         participants lost to follow up 
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Emotion regulation and self-control  
Axelrod, Perepletchikova, Holtzman and Sinha (2011) concentrated their 
study on the DBT principle that dysregulation of emotions is central to the 
dangerous impulsivity associated with BPD and is hence targeted as a primary 
mechanism of change in DBT. The researchers posited that an improvement in the 
ability to regulate emotions would lead to a decline in impulsivity, and this would be 
evidenced by a decrease in substance misuse, as having greater control of 
emotions thus being less impulsive should lead to a reduced need to regulate 
mood/self-medicate by using substances. This study investigated the above in a 
sample of 27 females with substance dependence and BPD who were receiving a 
20 week course of DBT in an outpatient service. The researchers assessed emotion 
regulation using the Difficulties in Emotion Regulation Scale (Gratz & Roemer, 2004) 
and recorded substance use for 30 days preceding treatment and for the last 30 
days of treatment, corroborated by weekly patient self-report, clinician assessment, 
urine toxicology and alcohol breathalyser tests. The study concluded that 
improvements in emotion regulation explained the variance in decreased substance 
use frequency. One way repeated measures ANOVAs indicated a significant 
interaction between frequency of substance use and emotion regulation (F (1, 21) = 
8.202, p = 0.009) and changes in substance use lost their significance when 
improvement in emotion regulation was controlled for (F (1, 21) = -0.112, p = ns). 
This demonstrates that improved emotion regulation in BPD patients treated with 
DBT can account for increased behavioural control using substance use as the 
outcome measure of behavioural control. 
While this is an interesting DBT study which has collected useful data about 
the relationship between increased emotion regulation skills and substance use, it 
has several limitations. Firstly, the authors use the term ‘behavioural control’ as their 
primary outcome measure but this is only measured by substance use. There are 
other aspects of behavioural control (impulsivity) relevant to the diagnosis of BPD 
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that could also have been measured to add more weight to the argument that 
increased emotion regulation skills gained via receipt of DBT act as a mechanism of 
change for improved behavioural control. Some obvious examples are evident in the 
DSM-5 criteria for BPD (American Psychiatric Association, 2013) under the section 
considering impulsivity which asks about impulsive sexual behaviour, reckless 
driving, uncontrollable eating and unnecessary overspending. Additionally, 
deliberate self-harm or suicidal ideation could have been measured to assess 
dangerous impulsive behaviour. The authors concede that the study is limited by its 
lack of a controlled treatment condition which of course impedes the possibility of 
attributing improvements observed in emotion regulation purely to DBT treatment. 
Further, most prior studies of DBT have provided a longer treatment period than that 
delivered by Axelrod et al. (2011). It is therefore unclear as to whether their study 
represented a full and comparable treatment ‘dose’ of DBT. A sample of just 27 
participants would be regarded as relatively small in the experimental literature and 
to ensure findings were more generalisable and statistically robust, a larger sample 
would be preferable.  
Similarly, the study’s all-female sample does not facilitate conclusions about 
emotion regulation in males receiving DBT treatment for BPD, although it is perhaps 
justified (and samples in other studies are also likely to be female-heavy) due to the 
larger number of treatment-seeking females diagnosed with BPD than males and 
the fact that current NICE (2009) guidance for BPD recommends the use of DBT 
treatment for females only. The female to male ratio for BPD diagnosis has most 
recently been estimated at 3:1 (American Psychiatric Association, 2000), however, 
this disparity has recently been called into question with suggestions that the gender 
balance may actually be more equally distributed (see, for example, Sansone & 
Sansone, 2011). The weaknesses in Axelrod et al.’s (2011) study design are 
reflected by their score of only 16/28 on Downs and Black’s (1998) checklist, the 
joint lowest score and below the average of 18.5.  
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Using data from the Cornell Personality Disorders Institute RCT (Clarkin, 
Levy, Lenzenwenger & Kernberg, 2004), Lenzenwenger, Clarkin, Levy, Yeomans 
and Kernberg (2012) set out to investigate the changes which occur in therapeutic 
treatment of BPD.  A sample of 58 predominantly female participants with BPD were 
randomly allocated to receive either DBT, Transference-Focused Psychotherapy 
(TFP) or a third condition, Supportive Treatment (SPT) which was intended to 
control for attention and support received. As well as regularly completing self-report 
measures, each participant was evaluated by an experienced clinician at baseline 
and subsequent three month intervals to assess change. The researchers 
discovered that participants showed change over time in several dimensions 
simultaneously and noted that these dimensions could be clustered into similar 
domains representing broader categories of change in functional/psychological 
features mostly relating to emotional and behavioural control. The three domains of 
change identified were aggressive dyscontrol, social adjustment/self-acceptance 
and conflict tolerance/behavioural control. Positive improvements were seen in all 
three areas following treatment with DBT, TFP or SPT suggesting that different 
areas of impaired functioning will change at different rates and that variables can be 
clustered into sets which will largely change simultaneously with other similar 
variables. In order to test whether treatment type was related to the three factors, 
the researchers conducted one-way ANOVAs on the three factor scores. These 
tests did not reveal any significant differences between treatment type (DBT, TFP 
and SPT: multivariate one-way ANOVA: p > 0.60; all univariate one-way ANOVAs: p 
≥ 0.40), suggesting that the same change domains were produced regardless of 
treatment condition.  
Lenzenwenger et al. (2012) do however concede that their sample size of 58 
is relatively small for their factor analytic methodology and that had they followed 
patients up over a longer time period than one year, different predictors of change 
may have been revealed. Nevertheless, reflected in its score of 20/28 on Down’s 
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and Black’s (1998) checklist, this is a solid study based on robust RCT data which 
corroborates previous studies’ evidence for emotion regulation and behavioural self-
control as central mechanisms of change in the treatment of BPD. It is important to 
emphasise, however, that these mechanisms of change were not found to be 
exclusive to the DBT treatment of BPD but occurred simultaneously in TFP and SPT 
also. 
Davenport, Bore and Campbell (2010) set out to investigate changes in self-
control in 17 (again, predominantly female) BPD patients. Participants were divided 
into two groups: a control group of individuals who were either on a waiting list for 
therapy, or who had started, but not completed, their first eight week skill-building 
module and a second group who had successfully graduated from a DBT program in 
the past three years. In this between-subjects design, two self-report measures of 
self-control were mailed to participants and status in treatment was used to allocate 
participants to either the control (pre-treatment) or treatment (post-DBT treatment) 
group.  Data supported the researchers’ hypothesis that pre-treatment participants 
would be significantly under-controlled in measures of self-control when compared 
to post-treatment participants and that post-treatment participants would be more 
conscientious and agreeable, when compared to pre-treatment participants. Overall, 
the research revealed significant personality differences between pre- and post-
treatment groups. Participants who had not yet received DBT had lower self-control, 
were less agreeable and less conscientious compared to the post-treatment group. 
Participants who had received DBT were just as self-controlled, agreeable and 
conscientious as the data used for normative comparisons. The researchers 
concluded that DBT appeared superior in aiding participants’ development of self-
control, suggestive of a more ordered personality.  
As with all between-subject designs, however, Davenport et al.’s (2010) 
study does not prevent the possibility of differences between the two groups 
accounting for the change, rather than the pre- and post-treatment variables. 
 27 
Randomisation was not used, and as with some of the previous studies, the sample 
size was small, limiting the generalisability and reliability of the data. Additionally, 
reliance on self-report methods to gain a measure of self-control opens up the 
possibility of response bias. This could have perhaps been corroborated using a 
behavioural measure and/or clinician report. These methodological oversights mean 
that Davenport et al.’s (2010) study achieved the lowest score of 16/28 on Down’s 
and Black’s (1998) checklist.  
Despite their limitations, the three studies summarised all provide empirical 
evidence for improvements in emotion regulation and behavioural self-control with 
DBT treatment. Changes within these domains are likely to produce more positive 
results in several outcomes of BPD symptomology. 
  
Skills use 
A key aspect of DBT is the teaching of specific behavioural skills with the aim 
of helping individuals to replace maladaptive behaviours with more adaptive 
responses (Linehan, 1993). However, Neacsiu, Rizvi and Linehan (2010) noted that 
no study to date had directly tested this mechanism of change and they therefore 
set out to investigate the improvement in skills on outcomes of BPD treatment. The 
study consisted of a female-only sample of 108 patients with BPD participating in a 
one year RCT with a four month follow-up period. Participants included 63 
recurrently suicidal women and 45 women with drug dependence but the 
researchers note that there were no significant differences in demographic 
characteristics between the suicidal group and the drug dependent group. 
Participants either received DBT or one of three control conditions: Community 
Treatment by Experts (CTBE), Treatment As Usual (TAU) or Comprehensive 
Validation Therapy (CVT), in conjunction with a 12-step program. Measures of DBT 
skills use, anger, suicidal/self-injurious behaviour and depression were gathered 
using a combination of self-report and semi-structured interviews. The researchers 
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used a hierarchical linear modelling approach to analyse their data. Although anger 
suppression and expression was not found to mediate outcome, significant 
mediation effects did indicate that the use of DBT skills fully mediated decreases in 
suicide attempts and depression symptom severity and an increase in the control of 
anger over time. The use of DBT skills also partially mediated the decrease of non-
suicidal self-injury over time. Participants who received DBT reported using three 
times more skills by the end of their treatment (mean DBT skills use increased by 
15.3%),  as compared to participants in receipt in one of the control conditions 
(mean skills use increased by only 4.6%). At follow up, DBT participants maintained 
their increased skill use but control participants had decreased their skill use by 5%.  
Although this data supports a DBT skills deficit model of BPD by 
demonstrating via robust methodology that improved skills use is a mechanism of 
change for suicidal behaviour, depression, and anger control, Neasciu et al.’s (2010) 
study is limited by its primary reliance on self-report as a measure of skills use. 
Some individuals may have over or underestimated their proficiency in using DBT 
skills. Assessing skills use on a daily basis using a more objective measure would 
increase the reliability of the findings. When using a standard mediation analysis, an 
assumption is made that there are no confounds manipulating the mediator and 
outcome (Robins & Rotnitzky, 2005) and it is possible that uncontrolled extraneous 
variables influenced the meditational analysis in this study such that an increase in 
DBT skills use was not the only variable influencing positive outcomes in suicidal 
behaviour, depression and anger control. Nevertheless, methodologically, this 
remains a robust study, reflected by the highest score awarded by Downs and 
Black’s (1998) checklist of 26/28.  
Gibbons et al. (2009) set out to examine what they considered to be 
theoretically important mechanisms of change in outcomes between psychodynamic 
and cognitive-based therapy. They were specifically interested in the acquisition of 
compensatory skills and self-understanding and perception. Thirty four patients with 
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a primary diagnosis of BPD received one year of a version of cognitive therapy 
tailored to BPD, Schema-Focused Cognitive Therapy. Although this was not 
described by the researchers as CBT per se, it is a form of cognitive therapy for 
BPD which is very similar to CBT, and quite different to DBT. No BPD patients 
received any type of dynamic therapy; this was reserved for patients with depression 
or anxiety in another arm of the research trial. Outcomes were measured using well-
known, validated self-report measures of depression, anxiety and quality of life. Self-
understanding as a mechanism of change was measured using two self-report 
questionnaires and acquisition of compensatory skills was measured using the 
Ways of Responding Questionnaire (WOR; Barber & DeRubeis, 1992) which 
presents eight different stressful scenarios to participants along with an initial 
negative automatic thought. Participants are required to state their feelings, thoughts 
and possible reactions to each scenario which is then rated by independent judges 
for the presence of a list of possible positive and negative compensatory skills. High 
inter-rater reliability and internal consistency of items was recorded by the 
researchers. The data for the effects of cognitive therapy for BPD showed no overall 
change in self-understanding across treatment (all p values < 0.1). However, the 
researchers did conclude that change in compensatory skills was apparent in the 
BPD group and that in particular, a decrease in negative compensatory 
responses/negative thinking co-occurred with symptom improvement. This large 
scale, robust clinical trial therefore demonstrated that the attainment of new skills 
acquired through cognitive therapy acts as a mechanism of change in BPD, 
improving the symptoms of depression and anxiety.  
As Gibbons et al.’s (2009) study was a generic trial which also included 
participants with a primary diagnosis of depression or anxiety, the outcome 
measures were perhaps too broad to capture some of the additional symptoms 
experienced by people with BPD. This could be improved by the inclusion of 
additional outcome measures testing concepts key to the diagnosis of BPD such as 
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impulsivity, anger, self-harm and interpersonal function. Like other studies included 
in this review, the present study relied heavily on the use of self-report measures 
which are open to biased responding, however the WOR (Barber & DeRubeis, 
1992) was rated by clinicians and found to have high inter-rater reliability, adding to 
the reliability of the measure of skills acquisition. The researchers concede that the 
relatively small within-study sample sizes and their associated limitations on 
statistical power for testing interactions meant that the use of a pooled database 
was not the best way to investigate mechanisms of change in specific treatments for 
specific diagnostic categories (in this case, cognitive therapy for BPD). This study 
nevertheless achieved a fairly high score of 20/28 on Downs and Black’s (1998) 
checklist.  
Perroud, Nicastro, Jermann & Huguelet (2012) investigated improved skills 
in mindfulness, a key component of DBT treatment for BPD. They examined 
changes in and correlates of mindfulness skills over a one year follow-up period 
including a four week dose of intensive DBT followed by ten months of standard 
DBT.  The researchers studied 52 participants (90% females) with a BPD diagnosis 
and administered the Kentucky Inventory of Mindfulness Skills (KIMS; Baer, Smith & 
Allen, 2004) which describes mindfulness in four discrete dimensions: observing, 
describing, acting with awareness and accepting without judgment. Standard self-
report measures of depression and hopelessness were also administered at regular 
time intervals, as were standardised diagnostic clinician-administered assessments 
of BPD psychopathology. Results showed that DBT was associated with an 
increase in mindfulness skills over time and that of the four dimensions of 
mindfulness, accepting without judgement was the only dimension found to 
significantly increase over time following statistical adjustment for potential 
confounds. Increases in accepting without judgement additionally correlated with 
improvement in BPD symptoms, suggesting that it is this specific mindfulness skill 
that acts as a mechanism of change reducing BPD symptomatology.  
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As before, Perroud et al.’s (2012) reliance on self-report as a measure of 
mindfulness opens the data up to the possibility of response bias and does not 
provide an accurate, objective measure of this skill, although this is perhaps 
something inherently difficult to measure objectively. Crucially, this study lacked a 
control group, limiting the possibility of drawing conclusions about whether observed 
improvements are exclusive to the acquisition of the accepting without judgement 
skill or whether they are partially or otherwise explained by a natural change in 
mindfulness skills and/or correlate with an uncontrolled confound. As only one of the 
mindfulness dimensions was found to increase significantly, the researchers could 
not conclude that mindfulness skills per se function as a mechanism of change in 
DBT for BPD symptomatology, rather that the specific skill of accepting without 
judgement becomes enhanced via DBT and may therefore function alone as a 
mechanism of change. These limitations therefore meant that this study achieved 
only a slightly above average score of 19/28 on Downs and Black’s (1998) checklist.  
The studies summarised above do in the main demonstrate that increased 
use of skills gained through either DBT (Neasciu et al., 2010; Perroud et al., 2012) 
or cognitive therapy (Gibbons et al., 2009) lead to favourable outcomes on self-
harm/suicidality, anger, depression, anxiety and standardised BPD symptomatology, 
providing compelling evidence for the deployment of skills acquired through 
therapeutic techniques as a mechanism of change in the treatment of BPD.  
Therapeutic alliance and investment in treatment  
Across a range of psychotherapies the therapeutic alliance is considered a 
helpful factor in retaining patients in therapy as well as contributing to positive 
outcomes (Horvarth & Luborsky, 1993). However, it remains a difficult concept to 
quantify and could easily be conflated with other mechanisms of change such that 
its role as an independent factor in its own right becomes less clear. The most 
sensible definition for considering therapeutic alliance as a mechanism of change 
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might be to measure a change in the alliance over time to show that as it develops 
(and hopefully improves) so BPD symptoms reduce - a positive, measureable 
outcome.  
Bedics, Atkins, Comtois and Linehan (2012) aimed to explore the therapeutic 
alliance as a mechanism of change in DBT for BPD. One hundred and one females 
were randomised to receive either DBT or a control condition, Community Treatment 
Delivered by Experts (CTBE). CTBE treatment was uncontrolled by the researchers, 
however, they note that, “selected therapists described their theoretical orientation 
as “eclectic” or “mostly psychodynamic” (i.e., there were no cognitive behavioural 
therapists in the CTBE condition)” (p.68). As well as meeting criteria for BPD, all 
participants included in the study had had a history  of self-harm defined by at least 
two suicide attempts or non-suicidal self-injury in the past five years and at least one 
incident in the past eight weeks prior to commencement of the study. The quality of 
the therapeutic alliance was rated by patients using the Structural Analysis of Social 
Behaviour (SASB; Benjamin, 1974). Results showed that in comparison to CTBE 
participants, DBT participants reported their therapists as increasingly more 
affirming, protecting, and controlling during treatment, supporting the researchers’ 
hypothesis. Additionally, DBT participants reported a stronger association between 
increased therapist affirmation and protection with decreased non-suicidal self-harm, 
showing that positive developments in the therapeutic alliance correlate with the 
positive and desired outcome of BPD symptom reduction (self-harm in this case).  
Despite the strength of the RCT data, the reasonable sample size and the 
use of multiple time points for the assessment of symptomatic change and the 
therapeutic relationship, Bedics et al.’s (2012) study is not without limitations. 
Assessment of BPD symptoms was limited to self-harm and the researchers note 
the value that further research could add in extending these results to other domains 
relevant to BPD such as interpersonal functionality and emotion regulation. 
Additionally, the reliability of the data is limited, being taken only from participants’ 
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perspective. Tighter control could be achieved by utilising therapists’ assessment of 
the therapeutic relationship, as well as that of an impartial observer, blind to the 
treatment condition to which each participant was randomised. Nevertheless, this 
study provides valuable, current data regarding the effect of the therapeutic 
relationship as a mechanism of change in DBT for BPD and methodologically 
scored above average on Downs and Black’s (1998) checklist (21/28). 
Turner (2000) tested the effects of DBT versus a Client-Centred Treatment 
control condition (CCT) in a naturalistic evaluation of 24 primarily female patients 
with a diagnosis of BPD. In order to understand its role in the differences in 
outcomes (depression, anxiety, anger, self-harm/suicidality, required hospitalisation 
days) between the two therapies, the quality of the therapeutic alliance was 
measured using the Helping Relationship Questionnaire (HRQ; Luborsky, 1984). 
Participants were randomly assigned to receive either DBT or CCT and outcomes 
were evaluated using a combination of self-report and a rating assessor who was 
blind to each participant’s treatment condition. Patients receiving DBT therapy 
showed greater improvement than patients receiving CCT regarding suicide and 
self-harm, depression, anger, and a decrease in the number of admissions to 
psychiatric hospitals. Importantly, the quality of the therapeutic alliance was found to 
account for significant variance in patients' outcomes across both DBT and CCT but 
no significant difference in therapeutic alliance was observed between the two 
treatments. This suggests that the alliance accounted for as much variance in 
symptom improvement as did the differences in the treatment conditions 
themselves.  
Turner’s (2000) study however, rated the quality of the alliance at one single 
time point rather than measuring a change (improvement) in alliance over time, 
making it harder to infer its role as a mechanism of change linked explicitly to the 
outcome of improved symptoms. Like other studies reviewed, this study relied 
heavily on self-report measures and used a relatively small sample size. However, 
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randomisation and use of a control group add to its reliability and validity, meaning 
that it scored fairly highly on Downs and Black’s (1998) checklist (21/28).  
Wenzel, Chapman, Newman, Beck & Brown (2006) proposed that change in 
dysfunctional beliefs, reduction in hopelessness, and improvement in attitude toward 
treatment all function as mechanisms of change associated with CBT. The 
researchers used data from their open cognitive therapy trial (Brown, Newman, 
Charlesworth, Crits-Christoph & Beck, 2004) which consisted of a primarily female 
sample of 32 patients diagnosed with BPD. Clinical evaluations were conducted at 
baseline, six months and 12 months then again six months after treatment was 
terminated at 18 months. Baseline assessments involved clinician-administered 
interviews, self-report questionnaires and review of previous treatment records in 
order to ascertain participants’ diagnoses, suicide risk, psychiatric history and 
current physical, psychological, and social adaptation. Attitude towards treatment 
was measured using the Attitudes and Expectations Questionnaire (ERQ) which 
was adapted from Elkin et al. (1989). Results showed that 66.7% of the patients who 
had positive attitudes toward treatment no longer met criteria for BPD after 12 
months of treatment, as compared to only 14.3% of the patients who had a negative 
attitude toward treatment, suggesting that a positive view of therapy may be one of 
the factors influencing a reduction in BPD symptomology.  However, this may be a 
spurious link; it is not clarified how changes in attitude towards treatment specifically 
influenced outcome and without the benefit of data obtained at more than one time 
point in order to measure how a change in attitude associates with a reduction in 
symptomology, it is perhaps not reliably classed as a mechanism of change in the 
CBT treatment of BPD. The researchers additionally investigated other factors which 
they hypothesised to be functioning as mechanisms of change in the CBT treatment 
of BPD concluding, in support of their hypotheses, that a reduction in hopelessness 
was associated with significant reductions in borderline beliefs between baseline 
and termination. However, this conclusion may not be shedding much light on the 
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specific processes by which change occurs, as both belief change and reduction in 
hopelessness might be more reliably conceived as outcomes rather than 
mechanisms of change.  
Wenzel et al.’s (2006) relatively small sample size precludes the possibility of 
making generalisable inferences about the mechanisms of change in CBT for BPD 
to wider samples and the standard critique of self-report measures also applies, 
although this study sought to use clinician-administered assessments and reviews to 
counteract self-report. According to Downs and Black’s (1998) checklist, this study 
obtained an average score of 19/28.  
Together, these three studies provide some evidence that a strong 
therapeutic alliance and a positive attitude towards and investment in treatment are 
in some way associated with change in BPD symptomatology in both DBT (Bedics 
et al., 2012; Turner, 2000) and CBT (Wenzel et al., 2006) although the exact 
mechanisms of change at work are somewhat unclear.     
 
Discussion 
Despite a continuously expanding evidence base demonstrating the clinical 
effectiveness of both DBT and CBT in treating BPD pathology over the past twenty 
years, very little is known about the mechanisms of action by which these 
documented positive changes take place. This review sought to evaluate the 
relatively few empirical studies available that have investigated the processes by 
which therapeutic change occur in these therapeutic treatments for BPD.  
The nine studies reviewed could be broadly classified into three categories of 
change: i) emotion regulation and self-control (Axelrod et al., 2011; Davenport et al., 
2010; Lenzenwenger et al., 2012), ii) skills use (Gibbons et al., 2009; Neasciu et al., 
2010; Perroud et al., 2012) and iii) therapeutic alliance and investment in treatment 
(Bedics et al., 2010; Turner, 2000; Wenzel et al., 2006).  
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The first category was primarily concerned with how individuals benefit from 
a therapeutic approach geared towards helping them to recognise, understand and 
better regulate their emotions and moods, and to exercise self-control with regard to 
impulsive behaviours. The three studies that primarily investigated mechanisms of 
change relevant to these domains were solely concerned with DBT; there was no 
CBT study investigating emotion regulation improvements in BPD. Although all three 
studies produced solid empirical evidence to support increased control and 
regulation of emotion and/or behaviour leading to favourable outcomes, 
Lenzenwenger et al. (2012) concluded that this mechanism of change was not 
unique to DBT – it was the same mechanism also identified in both SPT and TFP 
treatments for BPD. However, this category’s overriding finding of improved emotion 
regulation following DBT treatment is perhaps unsurprising given that Linehan’s 
DBT biosocial theory of emotion dysregulation views BPD as a disorder of persistent 
emotional dysfunction occurring largely due to deficits in the ability to regulate 
difficult emotions and because of emotional instability and vulnerability (Linehan, 
1993, see Figure 2, below). 
In their paper discussing the DBT treatment of emotion dysregulation in 
BPD, McMain, Korman and Dimeff (2001) agree that, “the primary goal in the first 
stage of DBT is to treat out-of-control behaviours that threaten the individual’s life, 
treatment, and quality of life” (p. 195).  They go on to discuss the techniques that 
DBT therapists employ in order to help their patients achieve better regulated 
emotions including exposure-based procedures, validation, and the enhancement of 
capacities such as diverting attention away from cues associated with negative 
emotions and beginning to observe, describe, and understand the function of their 
emotions. Accordingly, it is promising that all studies reviewed found evidence of 
increased emotional and/or behavioural self-control as primary mechanisms of 
therapeutic change, suggesting that this is a vital and necessary process in the 
successful DBT treatment of BPD.   
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Figure 2: The relationship between emotion dysregulation and borderline behaviour 
patterns according to Linehan’s (1993) biosocial theory 
 
In reviewing the evidence for skills use as a mechanism of change in the 
therapeutic treatment of BPD, results were also encouraging. Both Neacsiu et al. 
(2010) and Perroud et al. (2012) studied the acquisition of skills in DBT treatment for 
BPD and found that increasing DBT skills use partially mediated the decrease of 
non-suicidal self-injury over time (Neacsiu et al., 2010) and that an increase in use 
of the mindfulness skill of accepting without judgement correlated with improvement 
in BPD symptoms (Perroud et al., 2012). Neacsiu et al. (2010) were able to make 
stronger inferences about the use of DBT skills in their BPD sample because of the 
use of a control group who did not report the same high levels of skills use as the 
DBT group. Both studies support the skills deficit theory of BPD that underlies DBT 
(Linehan, 1993). Accordingly, in testing out the skills deficit model, Lindenboim, 
Comtois & Linehan (2007) studied 49 women to ascertain whether practice of 
behavioural skills taught in the group skills training component of their DBT program 
was partly responsible for positive treatment outcomes. In accordance with Perroud 
et al. (2012) they found that mindfulness skills and additionally, crisis survival skills, 
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were practiced most frequently by participants and that the majority of participants 
practiced their DBT-learned skills on most of their treatment days.  
Regarding the other treatment of interest, Gibbons et al. (2009) studied skill 
acquisition in cognitive therapy for BPD concluding specifically that compensatory 
skills used to achieve a reduction in negative cognitions correlated with BPD 
symptom improvement, which is perhaps not surprising as a reduction in negative 
thinking is a primary goal of CBT treatment. Moreover, Arntz (1994) lists ‘correction 
of thinking errors’ as one of five main components to be addressed in CBT for BPD.  
The final category concerned with therapeutic alliance and patients’ 
investment in their treatment proved problematic in terms of identifying specific 
processes which could reliably be classed as mechanisms of change. Wenzel et al. 
(2006) found that a positive attitude towards treatment was associated with a 
reduction in BPD symptomotology although it was unclear how much this factor 
alone was responsible for patients no longer meeting criteria for a BPD diagnosis 
following treatment. A more reliable finding might have been possible if attitude 
towards treatment had been measured at more than one time point, allowing for the 
effects of time on change to be incorporated into analyses. Bedics et al. (2010) and 
Turner (2000) both studied the effects of therapeutic alliance in DBT treatment for 
BPD, producing contradicting evidence on the importance of the alliance as a 
positive change process. Although both studies concluded that a more positively-
perceived therapeutic alliance led to improved outcomes for patients, when 
comparing the alliance in DBT to their control condition (CTBE), Bedics et al. (2012) 
found that the alliance was reported more favourably in DBT than CTBE whereas 
Turner (2000) found no significant difference between patient-reported therapeutic 
alliance between DBT and his control condition (CCT). Both studies reported a 
correlation between the therapeutic alliance with improved BPD symptoms and 
importantly Bedics et al. (2012) found that this was true for the most concerning of 
BPD symptoms, self-injurious behaviour. This fits with Linehan’s (1993) model as 
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instead of the invalidating environment that BPD patients are accustomed to, 
therapists provide warm and emotionally-validating environments which foster 
increased emotion regulation skills (as well as other increased skills use, described 
above) and decreased instability and impulsivity (manifesting in behaviours such as 
deliberate self-harm). Importantly, this conclusion regarding the necessity of the 
therapeutic alliance is in agreement with a recent review of factors predicting 
outcome in BPD treatment which listed a stronger therapeutic alliance as the main 
factor predicting therapy outcome for patients with BPD (Barnicot et al., 2012) and is 
particularly promising given the difficulty BPD patients have with interpersonal 
relationships which one would naturally assume would extend to the therapeutic 
relationship. However, as discussed above, a more convincing measure of 
therapeutic alliance as a mechanism of change would be to measure change in 
therapeutic alliance and attitude towards treatment longitudinally rather than cross-
sectionally to attempt to link that change with reduction in BPD symptomology.  
Martin, Garske and Davis (2000) conducted a large meta-analysis of studies 
measuring alliance and concluded that the overall relationship between the alliance 
and outcome is moderate but consistent regardless of any hypothesised confounds. 
They noted that the large and varied range of measures available all had adequate 
reliability regardless of the method used (independent rater, self-report or therapist 
report). Given that they found a large diversity in alliance measures available, 
research on the alliance may not always be reliable and easily replicable, perhaps 
partially accounting for why the papers reviewed here struggled to isolate and 
quantify the alliance as a reliable mechanism of change, and why there was no 
agreement regarding the superiority of the alliance in the two studies primarily 
investigating DBT. 
To conclude, this review of the mechanisms of change in both DBT and CBT 
treatment for BPD is a start in a long journey towards being able to confirm the 
mechanisms which effect change in these two treatments for this complex and 
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challenging disorder. Three broad categories of mechanism of change were 
identified which are well-explained by Linehan’s (1993) DBT biosocial model of 
BPD: initial deficits in emotion regulation and self-control are improved via the 
therapeutic alliance and investment in treatment which result in increased skills use 
leading to favourable outcomes on general clinical syndromes (depression, anxiety) 
and on measures of BPD symptomology such as self-harm, impulsivity, substance 
misuse and borderline beliefs. In this review the DBT model more aptly explains the 
mechanisms of change identified herewith than a CBT model, due to the 
aforementioned weighting in favour of DBT in the studies analysed, although with 
regards to the emotion regulation and therapeutic alliance categories, two studies 
found that these mechanisms identified were not unique to DBT, and held for control 
therapies too – SPT and TFP (Lenzenwenger et al., 2012) and CCT (Turner, 2000).  
In terms of limitations, this review was slightly diverted from its initial equal 
interest in both the CBT and DBT treatment of BPD because the studies included 
were heavily balanced in favour of DBT, likely due to its prominence in the most 
current clinical guideline for BPD (NICE, 2009). This does, however, suggest that 
further research into the mechanisms effecting change in the cognitive behavioural 
treatment of BPD is warranted, especially as NICE (2009) advises that should this 
data be produced, future revisions may recommend CBT for BPD. The empirical 
data reviewed has highlighted three categories of therapeutic change (emotional 
and behavioural regulation and control, increasing skills use and therapeutic 
alliance/investment in treatment) which were observed by more than one set of 
researchers. It has, however, also highlighted the difficulty in demonstrating 
causality, much of the evidence relying on associative relationships.  
Additionally, the majority of studies reviewed have revealed difficulties in 
obtaining large enough sample sizes and in establishing satisfactory scientific rigour 
from which to base their conclusions, evidenced by some relatively low scores on 
Downs and Black’s (1998) checklist. Further robust research and hypothesis testing 
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will help to corroborate the mechanisms identified in this review, concentrating future 
efforts on the most important and research-worthy processes of therapeutic change 
in DBT and CBT identified in this review as improved emotion regulation and 
increased skills use. This review has identified some agreement in the mechanisms 
of change in the DBT treatment of BPD but more studies investigating mechanisms 
of change in CBT for BPD would be useful, as would information on both SFT and 
MBT, given their likely inclusion in future NICE guidance for BPD treatment. Efforts 
to reliably prove the therapeutic alliance as a mechanism of change in its own right 
would additionally be beneficial, given that we know the therapeutic relationship is a 
factor influencing treatment outcome regardless of other variables which may 
influence this relationship (Martin et al., 2000). More consistent data documenting 
the role of therapeutic alliance in CBT for BPD in particular would be welcomed as 
Arntz (1994) posits that a primary tenet of CBT is to use the therapeutic relationship 
as an important path towards fostering more adaptive future interpersonal 
interactions, suggesting it should act as a useful change process in the CBT 
treatment of BPD. 
Clinically, further mechanism of change data will assist practitioners in 
focusing on those aspects of treatment that are most likely to lead to positive 
outcomes, particularly benefitting those for whom only brief treatments are available. 
Therapists would be able to focus their efforts on the techniques and aspects of 
DBT and CBT which have been reliably proven to function as therapeutic change 
mechanisms such as validating and naming difficult emotions in an effort to enhance 
emotional regulation and self-control, and teaching and promoting new skills through 
which to achieve this. Should the data on therapeutic alliance as a reliable 
mechanism of change be produced, further research could build upon this to 
ascertain the specific clinical techniques therapists could use to foster positive 
developments and changes in the alliance (and in attitude towards treatment) which, 
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together with the emphasis on the aforementioned mechanisms of change, would 
lead to positive therapeutic outcomes for those with BPD. 
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Abstract 
Aims: Patients receiving therapy for personality disorder (PD) are likely to disengage 
prematurely and little is known about factors predicting treatment completion. For those 
that do complete treatment, there is a lack of research regarding factors that predict 
outcome. Predicting both completion and outcome of treatment is important for service 
planning. This study therefore aimed to identify predictive factors in individuals receiving 
either Cognitive Behavioural Therapy (CBT) or Dialectical Behaviour Therapy (DBT) for 
their PD. 
Method: This is a correlational study of variables predicting dropout and clinical 
outcome from a naturalistic sample of 231 male and female patients receiving outpatient 
CBT or DBT in a specialist PD service. Clinical measures were collected at initial 
assessment and post-treatment. Information regarding demographics and attendance 
were gathered from NHS electronic notes systems. 
Results: Therapist expertise was revealed as the only significant predictor of treatment 
completion; therapists defined as more expert retained patients in treatment longer. 
Multiple hierarchical regressions revealed that better therapy attendance and having a 
more expert therapist predicted decreases in risk (suicide attempts/self-harm) and in 
number of PD diagnoses. Better attendance predicted a decrease in number of clinical 
syndrome diagnoses (e.g. anxiety/depression). The presence of comorbid substance 
misuse at initial assessment predicted increases in risk and number of PD diagnoses.  
Conclusion: The importance of therapist expertise in treatment completion appears to 
be somewhat novel and warrants future replication. Findings are in agreement with 
previous literature documenting poorer outcomes for those with comorbid substance 
misuse. Encouraging patients to comply with therapy attendance to the point of 
completion is crucial in order to obtain the best possible reductions in risk behaviour and 
PD/clinical diagnoses. Other patient variables that are likely to predict treatment 
completion and outcome should be considered by future research. 
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Introduction 
Personality Disorder (PD) is defined by the newest edition of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-5; American Psychiatric Association, 
2013) as, “an enduring pattern of inner experience and behaviour that deviates 
markedly from the expectations of the individual’s culture, is pervasive and inflexible, 
has an onset in adolescence or early adulthood, is stable over time, and leads to 
distress or impairment” (p. 645). The diagnosis of PD is rarely restricted to one PD 
(Tyrer & Ferguson, 2000) and currently, DSM-5 classifies PD into ten distinct 
diagnostic classifications.  Contrary to previous versions of the DSM which 
categorised PD onto its own Axis (Axis II) and placed clinical syndromes such as 
anxiety and mood disorders onto Axis I, since July 2013, the new edition categorises 
both clinical syndromes and PDs onto Axis I, with PDs forming their own subset of 
this Axis. Throughout the rest of this paper the former Axis I/Axis II distinction will be 
made using the terms ‘clinical syndromes’ (referring to mood and anxiety disorders 
such as depression) and ‘PDs’ (referring to any diagnostic category of PD). 
Collectively, the presence of clinical syndromes and PDs will be referred to as 
‘clinical comorbidity’ – any clinical and PD diagnoses the patient has in addition to 
their primary PD diagnosis.  
Using the Structured Clinical Interview for DSM-IV-Axis II (SCID-II; First, 
Gibbon, Spitzer, Williams & Benjamin, 1997), Coid, Yang, Tyrer, Roberts and Ullrich 
(2006) estimated the prevalence of PD to affect approximately five per cent of the 
population. While the current study is interested in all PDs (with the exception of 
schizoid or antisocial PD (ASPD) which are excluded from the service providing data 
for this study), it will focus primarily on Borderline Personality Disorder (BPD), 
largely because of its higher prevalence among patients presenting to services 
(Coid et al., 2006; de Ruiter & Greeven, 2000) and because of its prominence in PD 
treatment research (Feigenbaum et al., 2011). BPD has been defined as, “a 
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complex and serious mental disorder that is characterised by a pervasive pattern of 
difficulties with emotion regulation and impulse control and instability both in 
relationships and self-image” (Bateman & Fonagy, 2004; p.1). 
 
Current treatment of personality disorders 
Contrary to previous opinion which held that due to its entrenched nature 
and roots in childhood, PD was largely untreatable, there is now evidence to 
suggest that BPD and other PDs can be successfully treated using psychological 
therapy (e.g. Binks et al., 2006; Panos, Jackson, Hasan & Panos, 2013; Stoffers et 
al., 2012). Many research studies have attempted to ascertain the efficacy of 
different psychotherapies used for the treatment of BPD including Dialectical 
Behaviour Therapy (DBT; Linehan, 1993) for women which is currently the only 
treatment recommended for BPD by the National Institute for Clinical Excellence 
(NICE, 2009). NICE suggests that should the evidence base be produced, future 
revisions may advocate the treatment of BPD using Cognitive Behaviour Therapy 
(CBT; Beck, Freeman & Davis, 2004), Mentalization Based Therapy (MBT; Bateman 
& Fonagy, 2008; Bateman & Fonagy, 2004) and Schema Therapy (Kellogg & 
Young, 2006). DBT could be described as a third-wave form of CBT and has a 
growing large and robust evidence base (e.g. Bloom, Woodward, Sasmaras & 
Pantalone, 2012; Feigenbaum et al., 2011; Feigenbaum, 2007; Kliem, Kröger & 
Kosfelder, 2010; Linehan et al., 2006a; Panos et al., 2013). Likewise, strong bodies 
of empirical evidence reliably document the effectiveness of both generic CBT 
(Butler, Chapman, Forman and Beck, 2006) and CBT specifically for BPD (Davidson 
et al., 2006). The current study focuses solely on the CBT and DBT treatment of PD.  
CBT is a structured, time limited, problem-focused treatment that uses 
traditional cognitive and behavioural techniques to teach patients to identify 
dysfunctional thoughts and core beliefs and to learn to challenge and modify them. 
CBT for BPD focuses particularly on altering core beliefs and is described by 
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Davidson et al. (2006) as less intensive with regards to therapist time than other 
forms of psychotherapy developed for BPD, such as DBT. A large randomised 
controlled trial (RCT) of individual CBT for BPD verses treatment as usual (TAU) 
found that CBT was roughly equivalent to TAU on most outcomes (including 
depression) and superior on outcomes of state anxiety, dysfunctional core beliefs 
and quantity of suicidal acts at two year follow-up (Davidson et al., 2006). 
Leichsenring and Leibing’s (2003) meta-analysis reported significant effects for a 
reduction in depressive symptoms for CBT treatment for PD over that of 
psychodynamic therapy for PD. Weinberg, Gunderson, Hennen and Cutter (2006) 
developed and studied a form of cognitive therapy, Manual Assisted Cognitive 
Treatment (MACT) aimed specifically at treating self-harming or suicidal patients 
with BPD. Their findings demonstrated that MACT was associated with significantly 
less frequent deliberate self-harm at the end of treatment as well as less severity of 
self-harm at six month follow-up. Using the same treatment programme, Freije, 
Dietz and Appelo (2002) found improvements in borderline symptoms, global 
function, depression, anxiety and interpersonal sensitivity in 85 patients with BPD.  
Developed by Linehan (1993), DBT uses strategies from CBT to develop and 
generalise emotion regulation skills as well as teaching distress tolerance and using 
third wave approaches such as Mindfulness (Kabat-Zinn, 1994) to promote 
awareness and acceptance. The DBT model posits that problems encountered by 
the individual are a result of emotion dysregulation which is maintained by certain 
personal and environmental reinforcers, integrating a biopsychosocial understanding 
of factors contributing to maladaptive behaviour. DBT aims to teach the necessary 
skills for effective interpersonal function and self-regulation (Winston, 
2000). Sessions are delivered both in weekly individual format and through skills 
development groups to maximise patient benefit, and are therefore more time-
intensive for both the patient and the therapist.  
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To date several RCTs and naturalistic studies have demonstrated the efficacy of 
DBT for BPD (e.g. Feigenbaum, 2007; Koons et al., 2001; Linehan et al., 2006a; 
Verheul et al., 2003) and these findings have been pooled and confirmed by recent 
meta-analyses (Kliem et al., 2010; Öst, 2008; Panos et al., 2013) and systematic 
reviews (Binks et al., 2006; Bloom et al., 2012; Stoffers et al., 2012), although a 
need for replicatory studies persists (Stoffers et al., 2012).  
 
Randomised controlled trials verses naturalistic outcome studies 
It is important to note the crucial role of RCTs in establishing an evidence 
base for the effectiveness of psychotherapeutic treatment for PD (e.g. Bateman & 
Fonagy, 2008; Bateman & Fonagy, 1999; Davidson et al., 2006). Due to their tight 
control of extraneous variables, randomisation to comparison groups and the 
‘blinding’ of participant, observer and sometimes researcher, RCTs have typically 
been considered the ‘gold standard’ of research studies and accordingly occupy the 
uppermost position in the hierarchy of evidence that organises healthcare research 
(described by Pistrang, Barker & Elliott, 2002). However there is a distinction 
between what can be concluded through a tightly controlled RCT with high internal 
validity (research efficacy) verses the conclusions which can be drawn from a less 
controlled but more generalisable and externally valid clinical effectiveness study 
(Pistrang et al., 2002; Roth & Fonagy, 2005; Seligman, 1995).  There has been, and 
continues to be, a strong debate over which is more useful, both in general medicine 
(Grapow, von Wattenwyl, Guller, Beyersdorf & Zerkowski, 2006; Rothwell, 2005) 
and in psychotherapy (Chambless & Hollon, 1998; Fonagy, 1999; Leichsenring, 
2004; Roth & Fonagy, 2005; Seligman, 1995), with researchers noting how vital it is 
for research studies to reflect ‘real-world’ healthcare provision, providing more 
generalisable and useful findings (Binks et al., 2006; Feigenbaum et al., 2011). 
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Predictors of treatment completion  
It is widely accepted that patients with PD are difficult to treat due to their 
tendency to engage in behaviours that interfere with the therapeutic process such as 
irregular attendance, disengagement and premature dropout from treatment 
(Fonagy & Bateman, 2006). Keeping patients attending therapy long enough to 
achieve beneficial effects is therefore a key treatment aim, particularly as non-
completion hinders the patient’s chance of symptom improvement (McMurran, 
Huband & Overton, 2010).  
Linehan et al. (2006a) report that compared to a control treatment, DBT was 
twice as effective at retaining BPD patients in treatment (25% dropout rate in DBT 
verses 59% in control treatment) and similarly, Kliem et al.’s (2010) meta-analysis of 
16 studies of BPD treatment reported an overall dropout rate of 27%. However, in 
Feigenbaum et al.’s (2011) study of 26 patients entering DBT treatment only eleven 
continued to complete one year of treatment, an attrition rate of 58%, similar to that 
reported by Clarkin, Levy, Lenzenweger and Kernberg (2007). There is a large 
discrepancy in dropout rates between studies, and Barnicot, Katsakou, Marougka 
and Priebe’s (2011) meta-analysis of treatment completion in psychotherapy for 
BPD confirmed the same, concluding that this substantial variation remains 
unexplained and that further research into processes involved in treatment dropout 
or completion is warranted.  
Defining early dropout as completing less than three months of therapy, De 
Panfilis et al. (2012) found that of the 162 patients with BPD studied, one third 
dropped out early. They investigated only patient factors involved in early dropout 
and found that a history of suicide attempts predicted early discontinuation while 
comorbid eating disorders were protective from early dropout. Importantly this study 
excluded those with comorbid substance misuse which seems a crucial factor to 
consider given its known association with PD (particularly BPD (American 
Psychiatric Association, 2013)), and in light of previous findings which concluded 
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that current or previous substance use was associated with non-completion of PD 
treatment (Karterud et al., 2003; Linehan et al., 2002; Linehan et al., 1999).  
Barnicot et al.’s (2011) meta-analysis of psychotherapeutic treatments for 
BPD found that only eleven of the 41 studies they examined investigated predictors 
of treatment dropout and that there was thus far very little evidence on predictors. 
Nevertheless, they reported that no patient sociodemographic variables (age, 
gender, employment status) were associated with attrition from therapy for BPD. 
McMurran and colleagues (whose work typically targets forensic and ASPD 
populations, in contrast to Barnicot who focuses more on BPD) conducted a 
systematic review of non-completion of PD treatments which concluded that non-
completion was associated with younger age, lower education level and 
unemployment, as well as with having more PD diagnoses, meeting a higher 
number of PD criteria, and having a more severe level of depression (McMurran et 
al., 2010). Feigenbaum et al. (2011) found that patients with comorbid PDs, 
(specifically paranoid PD and ASPD) comprised the majority of their high dropout 
rate. 
This suggests that, for some PDs at least, as well as demographic variables, 
overall comorbidity (both clinical syndromes and PDs) is likely to reduce treatment 
adherence although this may depend on the type of comorbidity and the primary 
diagnosis of the sample population as opposing findings have been reported (De 
Panfilis et al., 2012). Research on predictors of treatment completion to date has 
varied substantially and clarification of these factors is a worthwhile endeavour. 
 
Predictors of treatment outcome 
Despite a growing body of research into the treatment of PD, very little is 
known about predictors of treatment outcome (Robins & Chapman, 2004). Robins 
and Chapman (2004) summarise possible predictors in DBT treatment to involve 
characteristics of the patient, characteristics of the therapist and characteristics of 
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the combination of patient and therapist (including therapeutic relationship). Ryle 
and Golynkina (2000) investigated time-limited CAT for BPD concluding that worse 
outcomes were associated with greater severity of borderline features, a history of 
cutting, alcohol abuse and unemployment although more recent research using a 
novel treatment1 has concluded that better outcomes for clinical symptoms were 
obtained for those with more severe BPD symptoms at baseline (Black et al., 2009). 
A recent systematic review by Barnicot et al. (2012) investing factors which predict 
outcome of psychotherapy for BPD (psychotherapy consisted mainly of CBT, DBT, 
MBT and transference-focused psychotherapy) concluded that the therapeutic 
alliance was the most important common factor in predicting patients’ therapeutic 
outcomes.  
 
Outcome variables 
Following successful treatment of PD, previous studies have recorded 
improved outcomes in post-traumatic stress disorder (PTSD) symptom severity 
(Feigenbaum et al., 2011), self-harm and suicidality (Bohus et al., 1999; 
Feigenbaum et al., 2011; Linehan et al., 2006a; Linehan, Tutek, Heard & Armstrong, 
1994; Low, Jones, Duggan, Power & MacLeod, 2001; Sanislow & McGlashan, 
1998), interpersonal function (Linehan et al., 1994), anger reduction (Koons et al., 
2001; Linehan et al., 1994), reduced psychiatric inpatient hospital admissions 
(Linehan et al., 2006a; Linehan et al., 1994) and a decrease in symptoms of 
depression and hopelessness (Koons et al., 2001).   
 
 
 
                                                          
1
 Systems Training for Emotional Predictability and Problem Solving (STEPPS; Blum et al., 2002). A 
group treatment combining CBT, skills training and a systems element which involves family, friends 
and other people who feature regularly in the patient’s life.  
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Current study 
Given the importance of studying clinical effectiveness within the parameters 
of a ‘real-world’ National Health Service (NHS) PD service, the current study sought 
to investigate and identify the factors which influence treatment completion and 
treatment outcome in psychological therapy for BPD and other PDs. Data was 
generated by an established, dedicated NHS PD service over a period of eleven 
years and for the present analysis spanned a period of six years (2008-2014). It is of 
particular interest to identify factors which can predict treatment completion and 
treatment outcome to better understand for whom treatment is likely to work, and 
who would benefit from additional interventions/adaptations to facilitate their 
engagement and improvement.  
Based on the existing literature, the following variables were considered as 
potential predictors of treatment completion and/or outcome: 
Therapeutic dose2. Number of sessions attended can be thought of in terms 
of therapeutic dose which is likely to be a predictive factor as it is has been 
demonstrated that different conditions begin responding at different doses of 
therapy. Howard, Kofta, Krause and Orlinksy (1986) found that a positive response 
in depressive patients began at the lowest dose of psychotherapy, anxious-neurotics 
at a somewhat higher dose and borderline-psychotics at the highest dosage of the 
three patient groups. Bowen, South, Fischer and Looman (1994) found that number 
of therapy sessions attended predicted a favourable outcome in patients with panic 
and agoraphobia in a behavioural/medication trial and in an RCT of CBT and 
imaginal exposure for patients with PTSD, Tarrier et al. (1999) concluded that 
patients whose symptoms worsened over time had a greater tendency to fail to 
attend sessions. With regards to PD treatment, McMurran et al.’s (2010) systematic 
                                                          
2
 Therapeutic dose (number of sessions attended) was considered a predictor in analyses of treatment 
outcome only, given that it is inherently related to treatment completion and therefore would not be a 
useful predictor in treatment completion analyses (see Hypotheses section, below). 
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review concluded that not completing treatment meant that patients received a much 
less effective therapy than those who completed. Good therapy attendance is 
therefore a factor likely to have a significant effect on treatment outcome.  
Therapist expertise. As well as patient variables, therapist factors should 
also be considered (Robins & Chapman, 2004) and could function as a predictor of 
treatment completion as well as outcome. Across 161 studies, Luborsky, Auerbach, 
Chauder, Cohen and Bachrach (1971) identified several therapist characteristics 
that influenced therapy outcome including experience, attitude/interest patterns and 
empathy. Collectively, these factors might be thought of as therapist expertise which 
is also likely to be influenced by training/professional development and receipt of 
supervision from a more experienced therapist There is little evidence documenting 
the role of therapist expertise in treatment completion although Feigenbaum et al. 
(2011) note a higher dropout rate in PD patients receiving DBT from a particular 
therapist who it was agreed had been delivering poor-quality DBT. Most of the 
literature on this subject appears to concern therapists treating clinical syndromes 
such as anxiety and mood disorders. Franklin, Abramowitz, Furr, Kalsy and Riggs 
(2003) studied the relationship between therapist experience and outcome in a trial 
of exposure and response prevention for Obsessive Compulsive Disorder (OCD) 
and found that there was no difference in mean post-treatment OCD severity scores 
between the least experienced and most experienced groups (0-1 years or more 
than 9 years experience). However, they did note that case assignment in their 
naturalistic study meant that at pre-treatment those patients with more severe and 
difficult-to-treat OCD were assigned to more experienced therapists. Andrews 
(2001) notes that, “although the relationship between therapist experience and 
outcome is not linear, there are indications that more experienced therapists are 
likely to retain their clients longer and are more helpful to seriously impaired 
patients” (p.108). Despite the lack of existing research confirming the role of 
therapist expertise, the present study sought to examine the role of therapist 
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expertise in PD treatment completion and outcome based on the assumption that 
more experienced therapists are likely to retain their patients in therapy for longer, 
delivering a higher quality of treatment than less experienced therapists.  
Comorbid substance abuse. Substance misuse is a common problem across 
most PDs, occurring in roughly two thirds of patients with BPD (Dulit, Feyer, Haas, 
Sullivan & Frances, 1990) and is in fact incorporated into one of the diagnostic 
features (impulsive and reckless behaviour) of BPD (DSM-5; American Psychiatric 
Association, 2013). Interestingly, Dulit et al. (1990) found that when substance 
misuse was not used as a diagnostic criterion for BPD, almost a quarter of patients 
no longer met DSM-IV (American Psychiatric Association, 2000) criteria for BPD. 
Westen, Novotny and Thompson-Brenner (2004) note the tendency for previous 
research to exclude difficult-to-treat BPD patients with comorbid substance misuse 
disorders regardless of it being a common feature of BPD. Substance misuse 
comorbidity has been reported to be associated with failure to achieve remission 
from BPD (Zanarini, Frankenburg, Hennen & Silk, 2003) and worse outcomes (Ryle 
and Golynkina, 2000) as well as with early and high levels of treatment dropout 
(Karterud et al., 2003; Linehan et al., 2002; Linehan et al., 1999). However, more 
promising results have been reported for recovery from substance abuse in people 
with BPD, suggesting that it may be possible to decrease some drug-related harmful 
behaviour that features in this group of patients, as well as to reduce overall 
psychopathology (Linehan, et al., 2002). An RCT of participants with BPD and drug-
dependence who received either DBT or TAU found that after 12 months of 
treatment and a 16 month follow-up, patients receiving DBT were abusing drugs at a 
significantly lower level than the TAU group (Linehan et al., 1999). Nevertheless, 
substance abuse is likely to have an effect on completion and outcome.  
Changes in the following treatment outcome variables were measured: 
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High risk behaviour. Several studies of PD treatment have reported a 
reduction in deliberate self-harm (DSH) and suicide attempts following treatment 
(Bohus et al., 1999; Bloom et al., 2012; Davidson et al., 2006; Feigenbaum et al., 
2011; Linehan et al., 1994; Low et al., 2001), an obviously desirable outcome. 
Clinical comorbidity3. Research has shown that mood disorders and 
substance misuse often co-occur with BPD (Afifi et al., 2011; Oldham et al., 1995; 
Skodol, Oldham & Gallagher, 1999; Widom, Czaja & Paris, 2009; Zanarini, 
Frankenburg, Hennen, Reich & Silk, 2006; Zanarini et al., 1998; Zimmerman & 
Mattia, 1999), as do other PD diagnoses (Afifi et al., 2011; Zanarini et al., 2006). 
This comorbidity has been shown to lead to higher dropout rates (Feigenbaum et al., 
2011), worse outcomes for people with BPD over a ten year follow-up period 
(Zanarini et al., 2006) and worse outcomes for treatment of mood disorders and 
other clinical syndromes when PD pathology is present (Reich & Vasile, 1993). 
Moreover, patients with comorbid PDs are reported to have more severe forms of 
these syndromes (Tyrer et al., 1990). 
Previous studies have showed that with successful treatment it is possible to 
reduce comorbidity, particularly depression and hopelessness, as well as symptoms 
characteristic of anxiety disorders (Freije et al., 2002; Koons et al., 2001). Links, 
Heslegrave and van Reekum (1998) found that 53% of patients followed-up for 
seven years no longer met diagnostic criteria for BPD and a large longitudinal study 
found at follow-up that two thirds of patients were clinically well with no clinical 
syndromes or PD diagnoses (Stone, Hurt & Stone, 1987). Following treatment, 
Sanislow and McGlashan (1998) reported fewer general PD symptoms and in 
patients treated with a combination of CBT and a systemic-based skills group for 
BPD, a reduction in BPD symptoms was noted (Blum, Pfohl, St. John, Monahan and 
Black, 2002; Freije et al., 2002), although a later Cochrane review found no change 
                                                          
3
 Clinical comorbidity was considered as a predictor variable in treatment completion analyses and as 
an outcome variable in treatment outcome analyses (see Hypotheses section, below). 
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in number of SCID-II-defined (First et al., 1997) PD diagnoses following six months 
of DBT treatment (Binks et al., 2006). It is likely that clinical comorbidity could have 
both an effect upon treatment completion as well as functioning as an outcome 
measure of treatment success.  
Based on existing research and literature, the following hypotheses were 
examined: 
 
Hypotheses 
Hypothesis 1: Predictors of treatment completion   
1. Clinical comorbidity (number of clinical syndrome diagnoses and number of PD 
diagnoses at baseline), therapist expertise, and baseline substance misuse will be 
predictive of treatment completion.   
Specifically,  
1a) Higher therapist expertise will be predictive of treatment completers.   
1b) Higher levels of clinical comorbidity will be predictive of non-completers. 
1c) The presence of baseline substance misuse will be predictive of non-completers.  
 
Hypothesis 2:  Predictors of treatment outcome 
2.1 Therapeutic dose, therapist expertise and baseline substance misuse will be 
predictive of changes in risk.  
Specifically,  
2.1a) Attending more sessions will be predictive of improvement in risk outcome. 
2.1b) Having a more experienced therapist will be predictive of improvement in risk 
outcome. 
2.1c) The presence of baseline substance misuse will be predictive of worse risk 
outcome.  
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2.2 Therapeutic dose, therapist expertise and baseline substance misuse will be 
predictive of change in PD clinical comorbidity (measured by change in number of 
PD diagnoses).  
Specifically,  
2.2a) Attending more sessions will be predictive of improvement in number of PD 
diagnoses.  
2.2b) Having a more experienced therapist will be predictive of improvement in 
number of PD diagnoses.  
2.2c) The presence of baseline substance misuse will be predictive of no 
improvement in or increase in number of PD diagnoses. 
 
2.3 Therapeutic dose, therapist expertise and baseline substance misuse will be 
predictive of change in clinical comorbidity (measured by change in number of 
clinical syndrome diagnoses).  
Specifically,  
2.3a) Attending more sessions will be predictive of improvement in number of 
clinical syndrome diagnoses. 
2.3b) Having a more experienced therapist will be predictive of improvement in 
number of clinical syndrome diagnoses. 
2.3c) Baseline substance misuse will be predictive of no improvement in or increase 
in number of clinical syndrome diagnoses. 
 
 
Method 
Design and setting 
The study used a pre- and post-treatment correlational design and took 
place in an NHS PD service. It was conducted as part of a larger naturalistic 
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investigation of outcomes for treatment of PD (Feigenbaum, in progress).  The 
outpatient therapy service offers adults and older adults with a diagnosis of at least 
one PD either CBT or DBT treatment which typically lasts for one year. Individuals 
whose primary diagnosis is schizoid PD, antisocial PD, moderate to severe learning 
disability, personality change due to head injury, or florid psychotic disorder are 
excluded.  
 
Sample size and statistical power 
It is conventional in psychological research to conduct a power analysis to 
determine the minimum sample size acceptable to achieve a given effect size. 
However, there are no generally agreed methods for relating the sample size to the 
number of predictor variables in a regression model and various ‘rules of thumb’ are 
used by different researchers (Field, 2009). Miles and Shevlin (2001) created a set 
of graphs which approximate sample size required to achieve different effect sizes 
with different levels of power based on number of predictors. Using the conventional 
power setting of 0.8 (Cohen, 1988), their graph recommends that a sample size of 
80 would detect a medium effect with three predictors. The current study achieved a 
sample size of 231 which should be large enough to detect a small to medium effect 
with the three hypothesised predictors. 
 
Participants 
Recruitment into the main study sample was conducted retrospectively. 
Sampling began by screening initial assessment reports, measures, online case 
records and correspondence of patients who were assessed by the service between 
2008 and 2013 to determine their suitability for inclusion. Patients who did not have 
completed measures detailing their clinical and PD diagnoses, risk behaviour, 
substance misuse, attendance and demographic information at baseline 
assessment were removed from the final analysis (n = 4). Six further patients were 
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not included in the study as they had not been diagnosed with PD at their initial 
assessment within the service. For patients who completed treatment the same 
process was used to extract data from discharge assessments and measures post-
completion. One hundred and seventy patients (74% of total sample) were 
categorised by their therapist as treatment completers and had data available both 
pre-treatment at baseline assessment and post-treatment at discharge assessment. 
A further subset of patients (n = 61, 26% of total sample) failed to complete their 
assessment, or completed the assessment but declined or dropped out of treatment 
before it was complete4.  
Table 1 presents demographic characteristics of treatment completers and 
non-completers at baseline assessment for the final sample of 231. Seventy eight 
per cent were female and 22% were male. Mean age at time of baseline 
assessment was 32.8 (s. d. = 10.6, range = 18-70). Patients in full-time college 
education or either part-time or full-time employment made up 23% of the total 
sample (n = 54). Seventy two per cent of the total sample classed themselves as 
White British, 9% as any other White background, 8% as Black or mixed White and 
Black, 8% as Asian or mixed White and Asian, and 3% as any other ethnicity.  
Prior to testing for significant differences between treatment completers and 
non-completers, demographic variables were tested for each of the groups using 
standard normality checks (histograms, skewness and kurtosis statistics and 
Kolmogorov-Smirnoff tests) and all were found to be skewed and significantly 
deviated from a normal distribution. Removal of outliers by calculating z-scores and 
removing cases more than three standard deviations above or below the mean did 
not return normal distribution samples on any variables, therefore non-parametric 
                                                          
4
 All patients included in analyses had previously been diagnosed with PD at their first point of contact 
with the service. Assessments that were not completed related to assessing patients’ suitability for 
therapy and further selection of either CBT or DBT treatment.   
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tests (Mann-Whitney U and Chi Square) were used to test for between-group 
differences.  
There was no significant difference in age at time of baseline assessment 
between treatment completers and non-completers (treatment completers: mean 
age = 33.3 years, s. d. = 10.7, n = 170; non-completers: mean age = 31.2 years, s. 
d. = 10.2, n = 61; U = 4559, p = 0.16, n. s.) or in gender (treatment completers: 
female n = 136, male n = 34; non-completers: female n = 45, male n = 16; 
2 
(1) = 
1.03, p = 0.31, n. s.). There was also no significant difference in ethnicity between 
the two groups (treatment completers: White British n = 130, any other ethnicity n = 
40; non-completers: White British n = 38, any other ethnicity n = 23; 
2 
(14) = 16.47, 
p = .29, n. s.) or in employment status at baseline (treatment completers: employed 
n = 40, unemployed n = 130; non-completers: employed n = 14, unemployed n = 47; 

2 
(1) = 0.008, p = .93, n. s.).  
Table 1  
Demographic characteristics of treatment completers and non-completers at baseline  
 
Demographic             Treatment completers (n = 170)                     Non-completers (n = 61)                                                
 
 
Female         136 (80%)                                       45 (74%)  
Male                                       34 (20%)                                           16 (26%)     
Age                       33.3 years ± 10.7 (range = 18-70)           31.2 years ± 10.2 (range = 18-54)                                       
Employed                              40 (23.5%)                                       14 (23%) 
Unemployed                        130 (76.5%)                                       47 (77%) 
White British                        130 (76%)                                           38 (63%) 
White Other                     10 (6%)                 10 (16%) 
Black or Black Mixed        12 (7%)                   6 (10%) 
Asian or Asian Mixed            13 (8%)                                               5 (8%) 
Any Other Ethnic Origin          5 (3%)                            2 (3%) 
 
 
A final test was conducted to check for any difference between the two 
groups based on number of PD diagnoses at baseline assessment and on the 
treatment type they received (CBT or DBT) to ensure there was no significant 
variation. Again, Mann-Whitney and Chi Square tests were used. There was no 
significant difference on number of PD diagnoses (treatment completers: mean 
number of PD diagnoses = 1.3, s. d. = 0.5, n = 170; non-completers: mean number 
of PD diagnoses = 1.2, s. d. = 0.4, n = 61; U = 4895, p = .36, n. s.). Not all non-
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completers were allocated a treatment type due to disengagement before allocation 
of treatment but of those non-completers who were allocated a treatment condition 
(n = 16) there was no significant difference between the two groups based on 
treatment type received (treatment completers: CBT n = 84, DBT n = 86; non-
completers CBT n = 8, DBT n = 8; 
2 
(1) = 0.002, p = .96, n. s). Tables 2 and 3 show 
treatment type (Table 2) and frequencies of each PD diagnosis (Table 3) for 
completers and non-completers at baseline.  
Table 2 
Treatment type of treatment completers and non-completers at baseline  
 
Treatment type                          Treatment completers (n = 170)         Non-completers (n = 61)                                                           
 
CBT                           84 (49.4%)          8 (13.1%) 
DBT                           86 (50.6%)          8 (13.1%) 
Not allocated treatment type                    0 (0%)                     45 (73.8%) 
 
 
 
Table 3 
Personality disorder profiles (SCID-II) of completers and non-completers at baseline 
 
PD diagnosis                               Treatment completers (n = 170)       Non-completers (n = 61)                                                           
 
Borderline                                                 162 (95.3%)                                  59 (96.7%) 
Avoidant                                                     17 (10%)                                      5 (8.2%) 
Dependent                                               11 (6.5%)                         1 (1.6%) 
OCPD                                                          8 (4.7%)                  3 (4.9%)                              
Paranoid                                                      6 (3.5%)                  1 (1.6%) 
Histrionic                                                      5 (2.9%)                   1 (1.6%) 
Narcissistic                                             4 (2.4%)                              0 (0%) 
Schizotypal                                                  1 (0.6%)                                      0 (0%) 
Mean number of PD diagnoses                   1.3 (s. d. = 0.5)                           1.2 (s. d. = 0.4) 
 
 
Ethics  
Ethical approval was sought from the local NHS Research Ethics Committee 
(REC) prior to the commencement of data collection. The study was given a 
favourable ethical opinion (REC Reference Number: 12/LO/0382; see Appendix B). 
Additionally, all patient correspondence from the service contains a phrase 
explaining that the service has an open file policy meaning that anonymised data 
may be used for research, service evaluation and audit purposes. All data was 
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treated in accordance with ethical guidelines pertaining to security and 
confidentiality of information.   
 
Procedure 
Data was collected retrospectively from various sources: clinical notes, 
online case record systems, electronic correspondence and reports and measures 
that therapists administered as part of baseline and discharge assessments.  
 
Measures5  
Suicide Attempts Self-Injury Interview (SASII) (Linehan et al., 2006b). The 
SASII was administered at baseline assessment (and post-treatment for treatment 
completers) to assess high risk behaviour (both DSH and suicide attempts). For 
non-completers, therapists were asked to complete the SASII based on their last 
contact with the patient prior to disengagement. The SASII is a semi-structured 
interview measure which breaks down the previous year into one month blocks, 
requiring the patient to recall the frequency of DSH and suicide attempts during 
each month of the last year. A calendar was used to point out significant dates, 
promoting optimum recall.  All episodes of DSH reported were recorded as a single 
incident of DSH, regardless of how close together each incident occurred. Suicide 
attempts were asked about in some detail in order to clarify the patient’s genuine 
intention to die (rather than representing a further incident of DSH), for example by 
asking, “did you leave a note?” and “did you expect to be found?” The SASII has 
been demonstrated to have good inter-rater reliability with high correlations across 
                                                          
5
 A number of other self-report measures not reported here were also administered at baseline and 
post-treatment as part of standard data collection per the service’s open file policy, and as part of a 
larger research trial (Feigenbaum, unpublished). The SASII, SCID-I and SCID-II have not been 
included in the appendices due to copyright protection.   
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assessor-rated items and good validity with concurrent measures of self-injury such 
as medical records (median item correlation r = 0.956; Linehan et al., 2006b).  
Structured Clinical Interview for DSM-IV-II (SCID-II) (First et al., 1997). The 
SCID-II is a structured clinical interview conducted at baseline (and at discharge 
assessments for treatment completers) to ascertain number and type of PD 
diagnoses. All therapists were fully trained in the use of SCID-II and random 
reliability checks were conducted monthly by the service’s clinical lead in order to 
assess inter-rater agreement. For non-completers, therapists completed the SCID-II 
based on the patient’s psychopathology at their last contact with the patient. 
Diagnostic criteria for each PD diagnostic category are established by the SCID-II 
using a range of trait-based questions and each trait is rated by the clinician as 
either “absent”, “possible” or “definitely present”. Test-retest and inter-rater reliability 
of the SCID-II have been extensively researched. Dreessen and Arntz (1998) 
produced high reliability scores in most subscales of the SCID-II using an outpatient 
population.  
Structured Clinical Interview for DSM-IV-I (SCID-I) (First, Spitzer, Gibbon & 
Williams, 2002). The SCID-I is a structured interview administered as part of 
baseline assessment (and discharge assessment for completers) in order to asses 
the number and type of clinical syndromes. All therapists received training in the use 
of SCID-I and again, random reliability checks were conducted at regular intervals 
by the clinical lead of the service. For non-completers, therapists completed the 
SCID-I based on the patient’s psychopathology at their last contact with the patient. 
The SCID-I interview assesses symptomology across a number of domains 
(including mood disorders, anxiety disorders and eating disorders) using questions 
to assess different traits of each diagnostic disorder which the clinician rates as 
either “absent”, “possible” or “definitely present”. The SCID-I is a lengthy and 
thorough diagnostic tool which research has shown to have high inter-rater reliability 
and high test-retest reliability for most subscales (Zanarini et al., 2000).  
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Therapeutic dose. This was quantified by recording the number of therapy 
sessions attended (which included both group and individual therapy sessions) as 
identified on the NHS RiO electronic notes system. 
Therapist Expertise. Therapists’ expertise was assessed by the clinical lead 
of the service (an international expert trainer in both CBT and DBT for PD), who 
rated therapists on a four point Likert scale (novice, experienced, adherent and very 
experienced, adherent and highly skilful) based on perceived level of expertise 
observed in supervision. This was corroborated using a combination of the following: 
scores on the CBT adherence rating scale (the Cognitive Therapy Scale-Revised 
(CTS-R); Blackburn et al., 2001), putative ratings of adherence using knowledge of 
the DBT competencies framework (available at www.ucl.ac.uk/CORE) and the DBT 
Expert Rating Scale (Linehan, Lockard, Wagner, & Tutek, 1996), the number of 
months the therapist had been working within the service, clinical supervision notes 
and consideration of professional development trainings attended. 
Christo Inventory for Substance-misuse Services (CISS). Christo, Spurrell & 
Alcorn, 2000). The CISS was used both pre-treatment at baseline assessment and 
post-treatment at discharge assessment for treatment completers. For non-
completers, therapists were asked whether or not patients were abusing substances 
at their point of disengagement with the service. This is a clinician-rated measure 
asking specifically about type and amount of substance use (including alcohol) in 
the 30 days prior to questioning only. Christo et al. (2000) report CISS test-retest 
and inter-rater reliability coefficients of 0.82 and 0.82, respectively. Information on 
patients’ substance misuse was also available for corroboration from the SCID-I. 
See Appendix C for copy of the CISS. 
 
Analysis 
Analysis was conducted using SPSS Statistics for Windows, Version 22.0 
(IBM, 2013). The sample was divided into two groups: those who completed 
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treatment and those who did not. Demographic variables were checked for normality 
and non-parametric tests were conducted to ensure there were no significant 
differences between completers and non-completers, as described above (see 
Participants section). Outcome variables were recoded and change between 
baseline and completion of, or dropout from, treatment was computed (see 
Computation of variables, below). All variables were checked to ensure parametric 
assumptions of normal distribution were met. Where this was not the case, 
transformations were considered (see Results, below). Using data collected both 
pre-treatment and at the point of dropout or treatment completion, the main analysis 
consisted of simple, logistic and multiple hierarchical regressions to test hypotheses. 
Given the large number of hypotheses generated, the number of analyses was kept 
to a minimum by combining hypotheses regarding separate predictors into the same 
regression for each outcome variable. 
 
Results 
Preliminary analysis  
Computation of variables. New variables were computed for risk, clinical 
comorbidity and therapeutic dose. Following collection of DSH and suicide attempt 
data from the SASII, each patient’s risk score was coded using the following system: 
severe risk (DSH weekly and more than one suicide attempt in the past 12 months, 
high risk (DSH at least monthly and one suicide attempt in past 12 months), 
moderate risk (DSH monthly or more frequently but no suicide attempts in past 12 
months), low risk (infrequent DSH no suicide attempts in past 12 months and no risk 
(no DSH and no suicide attempts in past 12 months). Change between pre- and 
post-treatment risk scores was then calculated (risk score at baseline minus risk 
score at treatment completion/dropout) to create one unique risk change variable 
where a higher score denoted a greater improvement in risk. Where patients’ risk 
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was higher at completion of treatment or point of dropout this was indicated with a 
negative score. In order to measure all scores on a positive scale, a value of three 
was added to every risk change score (minus three being the lowest score 
obtained).  
 Number of PD diagnoses was calculated at both baseline assessment and 
at post-treatment/dropout. Change between the two was calculated for all patients 
(number of PD diagnoses at baseline minus number at treatment 
completion/dropout) to produce a final PD diagnosis change variable where a higher 
score indicated a greater improvement in number of diagnoses. Again, to avoid the 
issue of negative values where patients’ number of diagnoses had increased, a new 
variable was computed which added a value of two to every risk change score 
(minus two being the lowest score obtained).The same process was followed for 
number of clinical syndrome diagnoses. In order to create one overall clinical 
comorbidity variable for the purpose of investigating the predictive value of 
comorbidity on treatment completion outcome, number of PD diagnoses was added 
to number of clinical syndrome diagnoses for all cases at baseline and post-
treatment/dropout.    
A final variable was computed for therapeutic dose/treatment completion 
which assigned a rank from one to five based on how many sessions patients 
completed and therapist identification of agreed completion of treatment (did not 
complete assessment, assessed and offered treatment but declined or referred 
elsewhere, began treatment but attended less than eight sessions, began treatment 
and attended eight or more sessions but did not complete and completed 
treatment).  
Normality checks of variables. All variables were checked for basic 
assumptions of normality both within the sample as a whole and separately for 
completers and non-completers. The independent variables therapeutic dose, 
therapist expertise and overall clinical comorbidity as well as the dependent variable 
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change in risk were found to be skewed in all analyses with significant deviations 
from normality noted on the Kolmogorov-Smifnoff test. The demographic variable 
age also showed negative skewness, marking a distribution significantly different 
from that of a normal distribution. For this reason, despite a small loss of power, it 
was decided that non-parametric tests would be used in correlational analyses 
involving these variables.  
Transformations and outliers. Due to the significant skewness described 
above, square root and log transformations were tested, albeit without success. 
Outliers were examined by calculating standardised z-scores for all skewed 
variables and even after removal of three extreme cases, data was still found to 
represent a significant deviation from the normal distribution for most variables. The 
sample therefore remained complete for regression analyses and normality checks 
on residuals were conducted following analysis.  
Normality checks within regression models. Hypothesis 1: logistical 
regression: standardised residuals were all within three standard deviations of the 
mean indicating no significant outliers so transformations or removal of outliers were 
unnecessary (n = 231). Hypothesis 2.1: multiple hierarchical regression: 
standardised residual z scores revealed two outliers both with a value less than 
minus three. Both cases were removed and the regression re-run (n = 229). This 
produced greater accounting of the variance by the predictors and a better fit of the 
model as well as a histogram more closely representing a normal distribution. 
Hypothesis 2.2: multiple hierarchical regression: standardised residual scores 
revealed no outliers greater than two standard deviations from the mean and the 
histogram of standardised residual scores looked broadly normal, therefore no 
outliers were removed, or transformations performed (n = 231). Hypothesis 2.3: 
simple regression: two outliers were revealed in standardised residual z scores, both 
more than three standard deviations above the mean. Following removal, a 
histogram appeared more normally distributed and the simple regression was re-run 
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(n = 229).  When hypotheses 2.1, 2.2 and 2.3 were analysed using a sample 
consisting of treatment completers only (n = 170), again two outliers were revealed 
in standardised residual z scores, both more than three standard deviations above 
the mean. Following removal of these two outliers, a histogram appeared more 
normally distributed and the three multiple regressions were re-run (n = 168).   
 
Hypothesis 1: Predictors of treatment completion   
Number of sessions attended ranged from zero to 165 and as can be seen in 
Table 4, clinical comorbidity was very similar between completers and non-
completers. Baseline substance misuse was higher in non-completers than in 
completers.    
Table 4 
Mean number of sessions attended, clinical comorbidity and substance misuse for treatment 
completers and non-completers 
         
                           Treatment completers (n = 170)       Non-completers (n = 61) 
  
 
Mean number of sessions attended          56.7 (s. d. = 34.1)                        5.5 (s. d. = 3.8) 
 
Clinical comorbidity mean                                          
(number of PD diagnoses plus number            2.7 (s. d. = 1.4)          2.9 (s. d. = 1.4) 
of clinical syndrome diagnoses) 
  
Percentage of patients using            46%                         59%  
substances at baseline 
 
Percentage of patients using                23%           54%                        
substances at treatment  
completion/dropout 
 
 
To test the hypothesis that baseline clinical comorbidity, therapist expertise 
and baseline substance misuse would predict treatment completion (completed 
verses did not complete), initial correlation of all variables was first explored to 
ensure that any significant relationships could be controlled as covariates. Table 5 
shows a correlation matrix which illustrates a high correlation between baseline  
Table 5 
Hypothesis 1: Predictors of treatment completion. Correlation matrix (Spearman’s r, n = 231) 
                   Patient variables                                                                                                                          Demographics                        
                             Baseline clinical comorbidity           Baseline substance misuse       Treatment completion       Age       Gender      Employment   
Patient variables 
 Baseline clinical comorbidity           ___     
 Baseline substance misuse            .152*      ___ 
     Treatment completion           -.071               -.111           ___ 
  Demographics 
 Age                                      .084                -.072                 .092         ___                                          
 Gender                     .066               -.023           .067                  -.016           ___ 
 Employment at baseline                -.099               -.039           .006                            -.051         -.033             ___ 
Therapist variables 
 Therapist expertise                       -.081                .092           .138*                  -.001          .010            -.119               
Note: Treatment completion = completed (1)/ did not complete (2). Baseline clinical comorbidity = number of clinical syndrome diagnoses + number of PD 
diagnoses at baseline. Therapist expertise = adherent and highly skilful (4)/adherent and very experienced (3)/experienced (2)/novice (1). 
*p < .05.   **p < .01. 
 clinical comorbidity and baseline substance misuse (r = 0.15, p < .05) which is to be 
expected because the SCID-I measure of clinical syndromes contains separate 
diagnostic categories which include substance misuse diagnoses. No association was 
found between either baseline clinical comorbidity and treatment completion (r = -.07, p 
= n. s.), nor between baseline substance misuse and treatment completion (r = -.11, p = 
n. s.), although an inverse relationship between both predictors and treatment 
completion existed confirming the hypotheses that clinical comorbidity and substance 
misuse form a negative relationship with completion outcome. Therapist expertise and 
treatment completion, however revealed a significant positive association (r = 0.14, p = 
.36). There were no significant associations between any of the demographic variables 
and treatment completion, nor between any of the remaining predictors so these were 
not controlled as covariates in any further analyses.  
The multicollinearity between the two predictors, baseline clinical comorbidity 
and baseline substance abuse is likely to pose a threat to the validity of multiple 
regression (Field, 2009) and the lack of significant association between both of these 
variables and treatment completion means that they are unlikely to contribute to the 
model’s ability to accurately predict treatment completion. Therefore, a logistic 
regression was conducted using therapist expertise only which produced a model that 
accurately predicted treatment completion category 74% of the time (given that 74% of 
patients did in fact complete treatment). Table 6 presents the regression coefficients 
(beta values), their standard errors and the model’s general statistics.  
Table 6 
Logistical regression exploring the role of therapist expertise in treatment completion 
 
                                                                           95% CI for exp b 
 
   B (SE)                      Lower           exp b        Upper 
Included       
Constant             -0.097 (0.59)               0.995           1.42          2.025 
                 
  Therapist expertise             0.35 (0.18)  
 
Note: R
2
 = .014 (Hosmer & Lemeshow, calculated by final model Chi-Square divided by original 
model -2LL), .016 (Cox & Snell), .023 (Nagelkerke). Model 
2
 (1) = 3.73.   *p < .05    
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The model showed that therapist expertise doesn’t predict treatment completion 
well enough to significantly improve on a 74% prediction rate (Wald 
2 
(1) = 3.74, p = 
.053, n. s.). Calculating an R-statistic6 produced a partial correlation of R = 0.08 
between therapist expertise and treatment completion which suggests that although a 
positive relationship exists between therapist expertise and treatment completion (such 
that as therapist expertise increases, so does the likelihood of completing treatment), 
therapist expertise makes a very minor contribution to the model, representing a small 
effect size (Cohen, 1988) and falling just below the threshold of a significant Wald 
statistic. Further exploration of this association was warranted and due to non-normality 
of the therapist expertise variable, a Mann-Whitney U test was conducted, revealing a 
significant difference in therapist expertise between the two groups (U = 4321, p = 
.036), suggesting, as was evident from the Spearman’s correlation, that therapist 
expertise has an impact on whether or not patients completed treatment.   
To confirm this association, a Pearson’s Chi-Square test was conducted which 
is designed to analyse two categorical variables. This test revealed a significant 
Pearson Chi-Square statistic demonstrating that therapist expertise and treatment 
completion are not independent and are therefore related in some way (2 = 8.144 (3), 
p = .043). In smaller samples where more than 20% of the expected frequencies are 
less than five (25% were less than five in the current analysis), it is conventional to 
report the Likelihood Ratio as well as the Pearson Chi-Square statistic, and 
accordingly, this Likelihood Ratio represents a slightly more significant effect (2 = 
8.455 (3), p = .037), confirming the association between therapist expertise and 
treatment completion. In order to examine this relationship more closely, the treatment 
completion category variable (see Computation of variables, above) was tabulated 
                                                          
6
 R-Statistic calculated using the formula: R =  ±     Wald – (2x df) (Field, 2009) 
              -2LL (original)        
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against therapist expertise, demonstrating that the greater the therapist’s expertise, the 
more likely patients were to attend more sessions and complete treatment (Table 7). 
Table 7 
Frequencies (percentages) of treatment completion category by therapist expertise level  
  
                            Therapist Expertise 
 
 
Treatment completion category       Novice       Experienced      Adherent and        Adherent and   
              very experienced      highly skilful  
 
Did not complete assessment           0 (0%)          4 (1.7%)           2 (0.9%)                  3 (1.3%) 
 
Assessed and offered treatment       0 (0%)          3 (1.3%)          10 (4.3%)                 6 (2.6%) 
but declined or referred elsewhere 
 
Began treatment but attended less   0 (0%)          3 (1.3%)            2 (0.9%)                 6 (2.6%) 
than 8 sessions 
 
Began treatment and attended 8 or   0 (0%)          4 (1.7%)          10 (4.3%)                8 (3.5%) 
more sessions but did not complete  
 
Completed treatment                        1 (0.4%)      37 (16%)           43 (18.6%)            89 (38.5%) 
 
Using overall baseline clinical comorbidity (number of clinical syndrome 
diagnoses plus number of PD diagnoses) as a proxy for patient complexity/clinical 
severity, it can be safely assumed that it was not the case that more complex patients 
were allocated to more expert therapists as a Spearman’s correlation (see correlation 
matrix, Table 5) revealed that there was no significant association between baseline 
clinical comorbidity and therapist expertise (r = -.081, p = n. s.) and that in fact this was 
a negative relationship suggesting that actually as therapist expertise increased, 
patients’ baseline clinical comorbidity decreased.  
 
Hypothesis 2: Predictors of treatment outcome (whole sample) 
An initial Spearman’s correlation was conducted to test associations between all 
variables. The correlation matrix in Table 8 shows a high correlation between gender 
and therapeutic dose (r = .179, p <.01) which is not surprising given the heavy 
weighting of the sample in favour of females. Females attended a mean of 47 sessions 
compared to a mean of 29 for males. Providing initial support for the hypotheses, 
strong associations were revealed between all three predictors and change in risk 
Table 8 
Hypothesis 2.1, 2.2 and 2.3: Prediction of treatment outcome. Correlation matrix (Spearman’s r, n = 231) 
                          Patient variables                                                                                                                                        Demographics                        
            Therapeutic dose Substance misuse  Comorbidity change–CS  Comorbidity change–PD  Risk change Age Gender  Employment 
Patient variables 
 Therapeutic dose         ___                 
 Baseline substance misuse   -.052               ___                        
     Comorbidity change – C         .273**      .050                      ___ 
 Comorbidity change – PD      .336**            -.137*        .320**             ___   
 Risk change           .482**            -.150*                    .106                        .358**             ___    
 Age                    .087               -.072                  .043            .052                        -.025         ___ 
 Gender          .179**             -.023                     .073             .070                         .093        -.016     ___ 
 Employment at baseline       -.026               -.039                    -.038             .009                                .009        -.051   -.033        ___ 
Therapist variables 
 Therapist expertise        .083      .092                    -.029             .147*                              .167*       -.001    .010       -.119 
Note: Comorbidity change – CS = number of clinical syndrome diagnoses at baseline - number at treatment completion/drop out. Comorbidity change – PD = 
number of PD diagnoses at baseline – number at treatment completion/drop out. Risk change = risk score at baseline - risk score at completion of 
treatment/drop out. Therapist expertise = adherent and highly skilful (4)/adherent and very experienced (3)/experienced (2)/novice (1).  
*p < .05.    **p < .01.                                                      
(therapeutic dose r = .482, p < .01; therapist expertise r = .167, p < 0.5; baseline 
substance misuse r = -.150, p < .05) and all three predictors and change in PD 
diagnoses (therapeutic dose r = .336, p < .01; therapist expertise r =.147, p < .05; 
baseline substance misuse r = -.137, p < .05) including, as expected, a negative 
relationship between both of these outcome variables and baseline substance 
misuse, suggesting that as substance misuse increased, risk score and PD 
diagnosis change score both decreased, indicating greater risk and more PD 
diagnoses. Only therapeutic dose was found to be significantly associated with 
change in clinical syndrome diagnoses, however (r = .273, p < .01). No demographic 
variables were found to correlate significantly with change in risk, change in PD 
diagnoses or change in clinical syndrome diagnoses. Change in PD diagnoses and 
change in clinical syndrome diagnoses correlated significantly with each other (r = 
.320, p < .01) which is not surprising given that it is well-documented that many 
features of clinical syndrome diagnoses are characteristic in PD. Table 9 shows the 
changes in risk, PD diagnoses and clinical syndrome diagnoses for treatment 
completers and for the sample as a whole between baseline and treatment 
completion/dropout.  
 
Table 9 
Frequencies (percentages) of change in risk, change in PD diagnoses and change in 
clinical syndrome (CS) diagnoses for treatment completers and sample as a whole. 
         
                               Treatment completers           Whole sample     
                                                        (n = 170)               (n = 231)            
 
Risk decreased from baseline                        141 (83%)                     144 (63%) 
 
Risk remains the same from baseline                  22 (13%)               77 (33%) 
 
Risk increased from baseline         7 (4%)               10 (4%) 
 
PD diagnoses decreased from baseline      84 (49%)                       89 (39%) 
 
PD diagnoses remained the same from baseline     81 (48%)              137 (59%) 
  
PD diagnoses increased from baseline        5 (3%)      5 (2%) 
 
CS diagnoses decreased from baseline      66 (39%)              100 (43%) 
 
CS diagnoses remained the same from baseline      85 (50%)              108 (47%) 
 
CS diagnoses increased from baseline       19 (11%)    23 (10%) 
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Hypothesis 2.1: Predictors of change in risk 
To test the hypothesis that therapeutic dose, therapist expertise and baseline 
substance misuse are predictive of change in risk, a multiple hierarchical regression 
was performed to see how much each predictor accounted for the variance in risk 
change. The correlation matrix (Table 8) shows that the highest correlation between 
change in risk and any of the predictor variables is with therapeutic dose (r = .482, p 
< .01) and this predictor was therefore entered first into the model before adding in 
therapist expertise and baseline substance misuse which were also both shown to 
be significantly correlated with risk change (substance misuse negatively as 
expected). After removal of outliers (see normality checks within regression models, 
above), the first model with just therapeutic dose produced an R2 of .151 
(accounting for 15% of the variation in risk change), demonstrating a significant 
change from zero (F (1, 227) = 40.32, p < .001). When therapist expertise and 
baseline substance misuse were added to the model, the variance in risk change 
explained by the three predictors together increased to 19% (R2 = .192), 
representing a significant improvement on the previous model (F (2, 225) = 5.085, p 
< .01). 
The first model using just therapeutic dose was significantly better at 
predicting outcome than the mean (F (1, 227) = 40.32, p < .001) as was the second 
model. All three predictors made a significant contribution to the model with 
therapeutic dose having the greatest impact (t (225) = 6.29, p < .001) followed by 
therapist expertise (t (225) = 2.52, p = .012) and baseline substance misuse (t (225) 
= -2.52, p = .012). It can therefore be concluded that although all variables did 
significantly predict change in risk, therapeutic dose was by far the greatest 
predictor explaining 15% of the total 19% variance.  Table 10 shows the regression 
coefficients (beta values), their standard errors and standardised beta values for 
both models, highlighting significant values. 
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Table 10 
Multiple hierarchical linear regression exploring the role of therapeutic dose, therapist 
expertise and baseline substance misuse in the prediction of risk change outcome 
 
                                B               SE B                 ß 
 
Model 1    
 Constant                  3.92                0.16    
 Therapeutic dose                 0.02                0.003                        .39** 
  
Model 2 
  Constant                  3.16                0.44    
  Therapeutic dose                           0.02                0.003            .38** 
  Therapist expertise                 0.32                0.13            .15* 
  Baseline substance misuse   -0.52                0.21           -.15* 
 
Note: R
2
 = .15 for Model 1. ∆R
2
 =.04 for Model 2. *p < .05   **p < .001 
 
Hypothesis 2.2: Predictors of change in clinical comorbidity (PD diagnoses)  
To investigate the hypothesis that therapeutic dose, therapist expertise and 
baseline substance misuse predict change in number of PD diagnoses, a multiple 
hierarchical regression analysis was performed.  As was the case with change in 
risk, the highest correlation between change in PD diagnoses and any predictor 
variable was with therapeutic dose (r = .336, p < .01) and this predictor was 
therefore entered first into the model before adding in therapist expertise and 
baseline substance misuse which were both also significantly associated with 
change in PD diagnoses (again, substance misuse showing a negative association, 
as expected). The first model using just therapeutic dose accounted for 8.5% of the 
variance in change in PD diagnoses (R2 = .085), a significant change from zero (F 
(1, 229) = 21.18, p < .001). Adding therapist expertise and baseline substance 
misuse to the model increased the variance in PD outcome explained by the 
predictors to 10.5% (R2 = .0105), not a significant improvement on the first model (F 
(2, 227) = 2.57, p = .079, n. s.). Although both models were significantly better 
predictors of change in PD outcome than the mean (Model 1: F (1, 229) = 21.18, p < 
.001; Model 2: F (3, 227) = 8.87, p < .001), only therapeutic dose made a significant 
contribution to the model (t (227) = 4.51, p < .001) and neither therapist expertise (t 
(227) = 1.59, p = .11, n.s.) nor baseline substance misuse (t (227) = -1.77, p = .08, 
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n. s.) did. Again, although all three variables were indeed predictors of change in PD 
diagnoses, therapeutic dose was by far the greatest predictor explaining 8.5% of the 
total 10.5% variance. Table 11 shows the regression coefficients (beta values), their 
standard errors and standardised beta values for both models, highlighting 
significant values.  
Table 11 
Multiple hierarchical linear regression exploring the role of therapeutic dose, therapist 
expertise and baseline substance misuse in the prediction of change in PD diagnoses 
 
                                B               SE B                 ß 
 
Model 1    
 Constant                  2.20                0.07    
 Therapeutic dose                 0.005                0.001                        .21** 
  
Model 2 
  Constant                  2.009                0.18    
  Therapeutic dose                           2.20                0.07            .28** 
  Therapist expertise                 0.08                0.05            .10 
  Baseline substance misuse   -0.15                0.09           -.11 
 
Note: R
2
 = .085 for Model 1. ∆R
2
 =.02 for Model 2. *p < .05   **p < .001 
 
 
Hypothesis 2.3: Predictors of change in clinical comorbidity (clinical 
syndrome diagnoses) 
As noted, the correlation matrix in Table 8 shows that of the three predictor 
variables, only therapeutic dose was significantly associated with change in clinical 
syndrome diagnoses (r = .273, p < .01).  A simple regression was therefore 
conducted to assess the impact of this single predictor on change in clinical 
syndrome diagnoses.  After removal of outliers (see normality checks within 
regression model, above), the regression showed that therapeutic dose accounted 
for 7% of the variance in change in clinical syndrome diagnoses, a significantly 
better predictor than the mean (F (1, 227) = 18.24, p < .001) and a significant 
contributor to the model (t (225) = 4.27, p < .001). Although therapeutic dose was 
the only predictor associated with outcome in this hypothesis, it did not have as 
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great an impact on change in clinical syndrome diagnoses as it did on change in risk 
and change in PD diagnoses.  
Table 12 shows the mean number of PD diagnoses and clinical syndrome 
diagnoses for completers and non-completers at baseline and treatment 
completion/dropout. Paired sample t-tests showed that the differences in mean 
number of diagnoses between baseline and treatment completion/dropout were 
significant for both completers (PD diagnoses: t (169) = 7.34, p < .001; clinical 
syndrome diagnoses: t (169) = 9.88, p < .001) and non-completers (PD diagnoses: t 
(60) = 2.19, p < .05; clinical syndrome diagnoses: t (60) = 2.73, p < .05), suggesting 
that there was some improvement for those who did not complete treatment, 
although it was not as great as for those who did. 
Table 12 
Change in clinical comorbidity. Mean number of PD and clinical syndrome diagnoses at 
baseline and at treatment completion/dropout for completers and non-completers  
 
Clinical comorbidity                             Treatment completers (n = 170)         Non-completers (n = 61) 
 
                                                                         
 
Mean number of PD diagnoses                      1.3 (s. d. = 0.5)                            1.2 (s. d. = 0.4) 
at baseline assessment 
 
Mean number of PD diagnoses at                  0.7 (s. d. = 0.6)                            1.1 (s. d. = 0.4) 
treatment completion/dropout 
 
Mean number of clinical syndrome               1.4 (s. d. = 1.2)                             1.7 (s. d. = 1.3) 
diagnoses at baseline assessment 
 
Mean number of clinical syndrome               0.75 (s. d. = 0.9)         1.4 (s. d. = 1.0)     
diagnoses at treatment completion/dropout 
 
Hypothesis 2: Predictors of treatment outcome (treatment completers only) 
Exploratory analyses were re-run using treatment completers only to assess 
differences in prediction of outcome. 
Change in risk 
A multiple regression showed that therapeutic dose, therapist expertise and 
baseline substance misuse together accounted for only 3.6% of the variance in risk 
scores in completers and that the model was not significantly better at predicting 
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change in risk than the mean (F (3, 164) = 2.07, p = .11, n.s.). None of the three 
predictor variables made a significant contribution to the model (therapeutic dose: t 
(164) = 1.49, p = 0.14, .n. s.; therapist expertise: t (164) = 1.72, p = .09, n. s.; 
baseline substance misuse: t (164) = -1.49, p = .014, n. s.).  
 
Change in PD diagnoses 
A multiple regression showed that all three predictors accounted for only 
3.8% of the variance in change in PD diagnoses and that the model was not 
significantly better at predicting change in risk than the mean (F (3, 164) = 2.19, p = 
.09, n.s.). Therapeutic dose was the only predictor which made a significant 
contribution to the model (t (164) = 2.22, p < .05) with neither therapist expertise (t 
(164) = 0.89, p = .38, n. s.) nor baseline substance misuse (t (164) = -1.29, p = .2, n. 
s.) having a significant impact.  
 
Change in clinical syndrome diagnoses 
A multiple regression showed that all three predictors together accounted for 
6.3% of the variance in change in clinical syndrome diagnoses. The model was 
significantly better at predicting risk than the mean (F (3, 164) = 3.68, p <.05) and 
again, therapeutic dose was the only predictor which made a significant contribution 
to the model (t (164) = 2.83, p < .01) with neither therapist expertise (t (164) = -1.47, 
p = .14, n. s.) or baseline substance misuse (t (164) = 0.34, p = .74, n. s.) 
contributing significantly.  
A sample consisting of just treatment completers, therefore, revealed that 
none of the variables accurately predicted change in risk and only therapeutic dose 
contributed to a regression model predicting change in number of PD diagnoses and 
change in number of clinical syndrome diagnoses. The model was slightly better at 
predicting change in clinical syndrome diagnoses than the other two outcome 
variables but still accounted for only a very small proportion of the variance in 
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change in number of clinical syndrome diagnoses. Table 13 presents the regression 
coefficients (beta values), their standard errors and standardised beta values for all 
three outcomes in treatment completers only, with significance values and R2 figures 
incorporated.  
Table 13 
Multiple linear regression exploring the role of therapeutic dose, therapist expertise and baseline 
substance misuse in the prediction of change in risk, change in PD diagnoses and change in 
clinical syndrome diagnoses in treatment completers only. 
 
                                B               SE B                   ß 
 
Change in risk   
 
 Constant      4.35    0.55              
  Therapeutic dose    0.005                            0.003      .12 
  Therapist expertise    0.25    0.15         .13 
  Baseline substance misuse  -0.36    0.24                -.12 
            
Note: R
2
 = .036. *p < .05   **p < .01 
   B               SE B                    ß 
 
Change in PD diagnoses 
                           
 Constant                              2.22                            0.26      
Therapeutic dose    0.004     0.002   .17* 
  Therapist expertise    0.06    0.07   .07 
  Baseline substance misuse  -0.02    0.11              -.10 
              
Note: R
2
 = .038. *p < .05   **p < .01   
         B               SE B                   ß 
 
Change in clinical syndrome diagnoses    
 
  Constant     2.75                0.41        
  Therapeutic dose    0.007                 0.003    .22** 
  Therapist expertise   -0.16                            0.11    .14 
  Baseline substance misuse   0.06                0.18   .74 
                   
Note: R
2
 = .063. *p < .05   **p < .01 
 
 
 
 
Discussion 
In agreement with previous similar studies (Kilem et al., 2010; Linehan et al., 
2006a), the current study reported an overall drop out rate of 26%. Results showed 
that, as hypothesised, more experienced therapists were able to retain their patients 
in treatment longer than less experienced therapists. Although this finding is in 
agreement with previous anecdotal evidence and opinion (Andrews, 2001; 
Feigenbaum et al., 2011), similar research did not reveal the same effect (Franklin 
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et al., 2003) and there has been little evidence to date documenting the role of 
therapist expertise in treatment completion or outcome. One hypothesis for the 
current study’s finding is that more expert therapists were better able to manage 
difficulties arising in early sessions, forging a more useful therapeutic alliance than 
less expert therapists. Quantification of therapist expertise will inevitably vary 
between researchers and studies as there is no universal method of defining this 
construct. Franklin et al. (2003) simply based their measure on number of years of 
experience as a practising therapist but other factors are likely to contribute such as 
quality of supervision, frequency and quality of training and level of difficulty attained 
in previous therapy cases. The current study attempted to incorporate all of these 
factors by using the clinical lead’s observations from clinical supervision and 
knowledge of each therapist’s achievements. Specifically, the use of the CTS-R 
(Blackburn et al., 2001) and expert knowledge of the DBT adherence rating scale 
(Linehan et al., 1996) and the DBT core competencies (available at 
www.ucl.ac.uk/CORE) reduced the possibility of subjective bias by introducing 
objective, validated rating scales. However, subjectivity was still an issue because of 
the clinical lead’s prior involvement with the service and its therapists (see 
Limitations, below).  
Patients who are defined as having more severe symptoms are likely to be 
allocated to more expert therapists which could potentially mask any effects of 
expertise (Franklin et al., 2003) although a non-significant association between 
baseline clinical comorbidity and therapist expertise revealed this not to be the case 
in the current study. In fact, although not a strong association, a negative 
relationship was revealed showing that more experienced therapists were actually 
more closely associated with patients with lower levels of clinical comorbidity. 
Moreover, due to the large geographical spread of the service, patients were 
allocated to therapists based on location which additionally mitigated against 
allocations based on expertise. In any case, there was still a large enough effect to 
 91 
observe that patients stayed in treatment longer with more expert therapists. This is 
encouraging, demonstrating that even in this difficult-to-treat population, the best 
therapists are still able to retain patients long enough for them to attend as many as 
165 sessions and in the majority of cases, to complete treatment. Given that 
therapeutic dose was revealed to be the primary predictor in outcomes of risk, PD 
diagnoses and clinical syndrome diagnoses, keeping patients engaged with and 
regularly attending the therapeutic process is extremely crucial in order for them to 
achieve the best outcomes (McMurran et al., 2010). 
Although previous research has shown that comorbid substance misuse 
leads to higher tendency to drop out from treatment (Karterud et al., 2003; Linehan 
et al., 1999) as does PD comorbidity (Feigenbaum et al., 2011) and that clinical 
comorbidity in general leads to worse outcomes for BPD treatment (Zanarini et al., 
2006), the current study found that neither clinical comorbidity nor baseline 
substance misuse was significantly associated with treatment completion outcome. 
There was a higher percentage of baseline substance misuse in non-completers 
(59%) than in completers (46%) although this was not great enough to represent a 
significant statistical effect. Mean number of PD diagnoses, clinical syndrome 
diagnoses and overall clinical comorbidity was very similar between completers and 
non-completers at baseline so any pre-treatment differences were unlikely to have 
affected completion outcome. This suggests that other variables are more likely to 
play a role in whether or not patients complete treatment.   
After establishing that patients receiving treatment with a more expert 
therapist are more likely to complete treatment, ascertaining how helpful completing 
treatment is was the next logical step. Using data for the whole sample, therapeutic 
dose, therapist expertise and baseline substance misuse were all found to be 
significant predictors of change in risk and change in PD diagnoses. Eighty three per 
cent of treatment completers and 63% of the whole sample had fewer DSH incidents 
and suicide attempts at the point of completion/dropout and 49% of completers saw 
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an improvement in their number of PD diagnosis following treatment. Therapeutic 
dose was the single predictor found to be responsible for most of the variance in 
these outcomes suggesting that the more sessions a patient attends the more likely 
they are to see an improvement in their incidents of DSH and suicide attempts and 
number of PD diagnoses. Again, therapeutic dose was found to be a significant 
predictor of change in clinical syndrome diagnoses, confirming the importance of 
retaining patients in treatment. As with treatment completion, having a more expert 
therapist predicted better outcomes in risk and PD diagnoses and in agreement with 
previous research (Ryle and Golynkina, 2000; Zanarini et al., 2003) baseline 
substance misuse functioned as a negative predictor contributing to increases in risk 
and number of PD diagnoses. These findings confirm the importance of facilitating 
patients’ attendance and compliance with treatment. Replication of substance 
misuse as a factor which leads to worse risk and PD outcomes for patients confirms 
the need to routinely screen patients for this at initial assessment in order to ensure 
that it can be well-monitored and if necessary treated prior to beginning treatment to 
ensure treatment offered has the best chance of good outcomes.  
 Neither therapist expertise or baseline substance misuse were found to be 
significant predictors of change in clinical syndrome diagnoses and results showed 
that for both completers and non-completers, the majority of patients’ number of 
clinical syndrome diagnoses did not change, echoing previous findings that these 
conditions are resistant to treatment in the presence of PDs (Reich & Vasile, 1993). 
Linehan et al.’s (1999) study of BPD treatment reported a baseline number of just 
over two and a half clinical syndrome diagnoses which was approximately one 
diagnosis more than the current study found. This suggests that clinical syndrome 
comorbidity was less severe in this sample than in previous samples and higher 
baseline levels might have been required to see a greater change with treatment. 
Therapists are trained explicitly in treating PD and although clinical syndromes are 
often comorbid (Afifi et al., 2011; Widom et al., 2009; Zanarini et al., 2006; 
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Zimmerman & Mattia, 1999), they were not the focus of treatment which is targeted 
at decreasing risk behaviour and symptoms characteristic of PD diagnoses.  
There is some overlap between clinical syndrome diagnoses and substance 
misuse as substance misuse can be accurately defined as a clinical syndrome 
diagnoses in its own right. Substance misuse halved from baseline to end of 
treatment for treatment completers and reduced by about 20% for the sample as a 
whole which, although promising, does not represent major change, therefore it is 
not surprising that this did not have a significant effect on change in clinical 
syndrome diagnoses.  
 All three analyses were re-run using just treatment completers which 
revealed that neither regression model using all three predictors was significantly 
better at prediction than the mean for both change in risk and change in PD 
diagnosis outcomes. Standardised beta values were significant only in the models 
that included non-completers for these outcomes. This suggests that the model 
needs the variance in outcome in order to more accurately predict these changes 
and that a sample skewed more towards improvement makes it difficult to detect 
changes using therapeutic dose, therapist expertise and baseline substance misuse 
as predictors. Further research investigating outcome in just those who complete 
treatment would be worthwhile in order to replicate the importance of these 
predictors in risk and PD outcomes. Using completers only reduced the sample size 
by more than one quarter to 170 which may have compromised power although 
previous findings indicate that a sample size above 80 should still have had enough 
power to detect medium effects (Miles & Shevlin, 2001). Analysing treatment 
completers only did produce a model that was able to predict variance in clinical 
syndrome diagnosis outcome using therapeutic dose, therapist expertise and 
baseline substance misuse as predictors although therapeutic dose was the only 
predictor significantly contributing to the model. In treatment completers therefore, it 
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was possible to observe a greater effect of number of sessions attended on change 
in clinical syndrome diagnoses. 
 A noteworthy secondary finding was that in both completers and non-
completers, a small proportion of patients’ risk, PD diagnoses and clinical syndrome 
diagnoses increased. In non-completers this can be easily explained by the fact that 
they either dropped out before receiving treatment or received a dose so small that it 
did not produce a useful effect; being left untreated exposed them to increased risk 
and symptoms. However, across all three outcomes there were patients who 
completed treatment yet effectively got worse in terms of risk and number of 
diagnoses. It is well-documented that treatment can destabilise patients, increasing 
their risk behaviour as they struggle to find an appropriate outlet to express affect 
relating to distressing early experiences (e.g. Bateman & Fonagy, 2003). This could 
also result in an increase in symptoms of clinical syndromes such as anxiety and 
depression. It would not be surprising for patients to also then meet criteria for other 
PDs in these circumstances, especially given the fact that it is not uncommon to 
meet criteria for more than one PD diagnosis at a time (Shedler and Westen, 2007), 
or to posses enough traits of other PDs to just sit below the threshold for diagnosing 
that PD. It is also possible that by discharge assessment, therapists had better 
understanding and knowledge of their patients (including patients who attended only 
a few sessions before dropping out) and were therefore more able to accurately 
assess their PD and clinical diagnoses, and risk, than they were at baseline. 
 
Limitations 
This study was limited by significant skewness in many variables, restricting 
its generalisability to wider samples. Age was skewed towards younger patients, 
ethnicity towards White British populations and gender heavily weighted in favour of 
females (although this is typical of BPD (American Psychiatric Association, 2013) 
which unsurprisingly made up the majority (~95%) of the current sample). There 
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was a significant association between gender and therapeutic dose and further 
examination revealed that females attended a third more sessions than males. It is 
well-documented that females engage more in help-seeking behaviour than males 
(e.g. Addis & Mahalik, 2003; Oliver, Pearson, Coe & Gunnell, 2005) so this is not 
unusual.  
It was also a limitation that a larger sample size could not be obtained given 
the amount of data available spanning many more years than it was possible to 
include. This was largely due to missing and incomplete data which additionally 
meant that several measures were not included in the final analysis as patient data 
for them was too sparse. This resulted in reliance on clinician-rated measures and a 
lack of self-report information which would have contributed a more subjective 
dimension to the data (Uher et al., 2012). Dichotomising the sample into those who 
completed treatment and those who did not has been criticised for contributing to 
further loss of power due to losing variability in the data set (DeCoster, Iselin & 
Gallucci, 2009) which was perhaps an issue contributing to the null findings that 
were discovered when only treatment completers were analysed. Additionally, it is 
possible that the multiple statistical tests conducted on this data inflated the 
likelihood of Type I error and replication of these findings with a larger sample could 
address this, as well as possibly reducing skewness in several variables. 
As mentioned, when carrying out a Pearson Chi-Square test (as was 
conducted to analyse the relationship between treatment completion and therapist 
expertise), if more than 20% of the expected frequencies are less than five, the test 
loses some of its power which can only be rectified by re-running the test using a 
larger sample. As this was not possible, the Likelihood Ratio was also reported 
which did reveal a more significant effect but it is likely that a stronger effect would 
have been exposed had a larger sample been obtained. This, again, highlights the 
need for replication with a greater sample size.  
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Computing the suicide attempt and DSH risk variable into a five point scale 
(severe, high, moderate, low and no risk) assumes that these categories form an 
interval scale and this variable was indeed treated as interval data for the purpose of 
calculating a risk change score and conducting subsequent regression analyses. 
However, it is possible that splitting the variable this way might be more 
representative of ordinal data and this may therefore have influenced the validity of 
the regression model.  
Like other studies of treatment for PD, attrition was a problem and although 
this creates variation in the data that allowed for useful comparison between 
different levels of treatment completion, it was problematic to obtain reliable and 
valid estimates of substance use, risk and clinical comorbidity in patients who 
dropped out of treatment without warning. One way of addressing this would be to 
take measures every session rather than just pre- and post-treatment, however, this 
could interfere with development of the therapeutic alliance which has been shown 
to be an important mechanism of change in PD treatment (Bedics, Atkins, Comtois 
& Linehan, 2012; Turner, 2000), as well as a factor likely to predict better BPD 
treatment outcome (Barnicot et al., 2012). Therapeutic alliance also possibly 
contributes to retaining patients in treatment long enough to receive beneficial 
effects, as described. Additionally, completing measures regularly is a time-
consuming process, particularly as the current study did not use self-report 
measures which could be independently completed in patients’ own time.  
Finally, an element of subjectivity was introduced in the ratings of therapist 
expertise because these ratings were completed by the clinical lead of the service 
whom, of course, had prior knowledge of each therapist’s approximate dropout rate 
before providing expertise scores. It is possible that this information affected ratings, 
even if only subconsciously. This could have been avoided by using a blind 
assessor with no prior knowledge of the service and its therapists. This independent 
rater could have scored therapist expertise by listening to session recordings and 
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using core competency charts and standardised, validated expert rating scales. 
Unfortunately this was not possible within the limits of this project, however, upon 
replication, this should be considered.  
 
Clinical implications 
Based on the finding that therapist expertise predicted treatment completion 
and that treatment completion (better attendance) as well as therapist expertise led 
to improved clinical outcomes, providing therapists with good supervision and 
relevant training and professional development opportunities is important. Findings 
from the first analyses present a problem in terms of using the data to predict which 
patients are more likely to complete treatment as neither of the patient variables 
were significantly related to completion outcome although it is noteworthy that both 
baseline clinical comorbidity and baseline substance misuse were negatively related 
to treatment completion suggesting that, albeit weakly, they were associated with 
non-completion. Should more convincing data be produced regarding these patient 
predictive factors, clinically, it could assist in decision-making regarding patients’ 
suitability for long-term therapy or prior allocation to alternative interventions such as 
substance addiction programs to target comorbidity. The significance of good 
attendance on outcomes of risk and clinical diagnoses confirms the importance of 
promoting patients’ engagement with their therapy in order that they have the best 
possible chance of achieving symptom improvement.   
 
Future research  
Future replication clarifying the role of therapist expertise in completion and 
outcome of treatment would add to its sparse evidence base. It would be useful to 
clarify the role of comorbidity and particularly substance misuse in dropout as most 
studies have focused on treatment outcomes rather than completion. Previous 
research (Barnicot et al., 2011; McMurran et al., 2010) has noted the role of patient 
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demographic variables in dropout and it would be useful to expand upon this. 
Replication with a larger sample would alleviate the potential for statistical errors 
and ensuring more equal groups of completers and non-completers would avoid 
introduction of further bias.  
Findings demonstrated by the current study illustrate the importance of 
identifying factors which can predict not just treatment completion but treatment 
outcome. Importantly, therapeutic dose and substance misuse were demonstrated 
to be useful predictors in risk and PD diagnosis change and it would be worthwhile 
to investigate a variety of other patient factors involved in outcome such as 
employment status and resilience factors. Given the existing evidence base 
regarding clinical comorbidity and substance misuse it would be worthwhile to 
conduct more detailed investigations into the different diagnostic categories and how 
they interact with different PD diagnoses during the course of therapy, to alter 
outcome. The current sample was heavily weighted in favour of BPD which is widely 
accepted as the most common PD diagnosis (Coid et al., 2006; de Ruiter & 
Greeven, 2000), however it would be valuable to obtain larger samples of patients 
with primary PD diagnoses other than BPD in order to see if the findings revealed 
herein still stand. Finally, patients in the current study were equally distributed 
between CBT and DBT treatment and although research to date has not 
demonstrated differences in outcomes between these treatments (Brazier et al., 
2006), using a variety of predictor variables among a larger sample may yield 
interesting results with regards to predicting what patient factors predict who is more 
likely to achieve better outcomes with which treatment. 
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Conclusion 
Although the current study did not identify any patient variables associated 
with treatment completion, results did demonstrate the importance of therapist 
expertise in retaining patients in therapy. Attending a higher number of sessions, 
having lower substance misuse at baseline and having a more experienced 
therapist predicted better outcomes with regards to reductions in DSH and suicide 
attempts and number of PD diagnoses. Better attendance predicted a reduction in 
number of comorbid anxiety, mood and other clinical disorders. There are several 
patient variables which future research should address in order to add to this 
evidence in predicting treatment completion and treatment outcome for personality 
disorder.  
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Introduction 
This critical review intends to identify and reflect upon some of the key 
issues that arose during the planning and implementation of this major research 
project. The main aspects to be considered are categorised under the following 
headings: joining an established research project, managing missing and incomplete 
data, the challenges of conducting research in a ‘real-world’ NHS personality 
disorder (PD) service and some general reflections on current issues within the field 
of PD research. Some recommendations and conclusions follow. It is hoped that 
discussion of these issues will aid future researchers investigating PD, highlighting 
where procedural improvements may be made to ensure the effectiveness and 
efficiency of future research.  
 
Joining an established research project 
This project was appealing not just because of its subject matter which is of 
great interest, but because of the obvious benefits of joining a project for which large 
amounts of data had already been collected over a number of years. By the time of 
data collection, data was available for over 2,000 patients which is invaluable in 
terms of providing strong statistical power and revealing solid relationships from 
which to make clinically important inferences. Given the timescale of most doctoral 
research projects, collecting and accessing data over such a large time period would 
not have been possible unless much of the data was already collected.   
This did mean, however, that the measures utilised by the service to collect 
data about its service users were fixed and non-negotiable, shaping the focus of the 
project towards specific research questions. This is not necessarily a disadvantage 
as measures were scientifically sound and reliable, comprising a battery which 
covered all aspects of behavioural change one might wish to investigate in a 
longitudinal study of PD therapy outcomes. The measures included in the wider 
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study struck a good balance between self-report questionnaires and clinician-rated 
scales and interviews, in accordance with recent guidance suggesting that it is 
important to obtain both subjective and objective ratings of psychopathology (Uher 
et al., 2012).  However, due to missing data, no self-report measures were included 
in the final analyses meaning that the study relied solely on clinician-rated 
measures, although interviews did of course rely on patients’ responses. The 
decision to exclude all self-report measures was made based upon how much data 
was missing for each measure and in all cases it was decided that incomplete data 
sets would cause too many difficulties with analysis, even with the aid of statistical 
techniques such as multiple imputation (Rubin, 2004; Sterne et al., 2009). There 
was scope to obtain rich information without the addition of other (mainly self-report) 
measures, although they doubtlessly would have added valuable input.  
Unfortunately, joining an established project meant that there was 
sometimes little that could be done to rectify problems with incomplete data. This will 
be considered in more detail below, but did represent a significant challenge in 
terms of obtaining complete and reliable data for a satisfactory number of patients. 
This highlighted the importance of following recent best-practice guidance regarding 
keeping good research records (Schreier, Wilson & Resnick, 2006), detailing my 
role in the data collection and collation process in order that searching for missing 
data need not be a lengthier process than necessary and so that at the end of my 
involvement, future researchers are able to understand clearly what has already 
been established.  
Although the benefits of having such a large amount of data readily available 
for analysis were clear, the challenge of transforming this data into something that 
could be usefully entered and analysed within the available time constraints meant 
that I often wondered whether it would have been easier to collect the data myself 
from the outset and this is a decision I would struggle to make should I begin the 
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project again with the benefit of hindsight. Collecting my own data would have 
avoided the problem of missing and incomplete information, but at the great 
expense of limiting the amount of data it would be possible to obtain, therefore 
reducing the validity of the clinical conclusions that could be drawn from the 
research.  
 
Missing and incomplete data 
Missing data was without doubt the largest problem encountered during the 
research process and although this is by no means unusual or disastrous in social, 
behavioural and health science research (Graham, 2012), the majority of statistical 
techniques assume (or require) complete data, and in its absence most commonly 
default to the least desirable option: deletion of the entire case from the analysis 
(Osborne, 2013). Collecting data for the current study was a time-consuming and 
laborious process so not including valuable data was disappointing.  
Although the disorganisation of the data was made clear at the 
commencement of my involvement in the project, it became apparent throughout the 
course of the research that in some cases the location of the data required for 
certain analyses was actually unknown. In terms of disorganisation, the first difficulty 
that occurred was that of questionnaires and interview measures that had not been 
correctly filed or labelled with a patient name or date and were thus unusable. Some 
data was labelled but not all measures from the standard test battery were present 
and complete. In this instance, it was possible in many cases to obtain the missing 
data by asking clinicians to search in other workspaces where data had been 
securely filed at earlier stages of the project. Where hard copies of the data could 
not be found, clinicians were often able to remember specific outcomes (for 
example, if patients had self-harmed following treatment completion or dropout, or 
whether they continued to meet diagnostic criteria for certain clinical syndromes and 
PDs). Where this was not an option, information could often be found on an 
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excellent electronic folder system on the services’ shared drive which contained a 
file for each patient complete with assessment/discharge summaries and 
correspondence. In many cases it was fairly easy to obtain missing data this way, 
albeit a lengthy process. For the most part, baseline data was present and usually 
fairly complete; post-treatment data however, was harder to obtain, and is obviously 
crucial for calculating change. With strategic approaches, it was possible in most 
cases to obtain some post-therapeutic missing data but was nevertheless a time-
consuming and tedious process. 
In some cases it was difficult to ascertain whether data available in hard files 
was collected pre- or post-treatment and in these instances, and where 
demographic information had not been properly entered onto measures prior to 
completion of the assessment, the electronic care records system (RiO) was utilised 
to match dates to measures. Although this system contains a wealth of information, 
finding the specific information required was again a lengthy process, taking up 
valuable time that could have been put to better use collecting and entering data for 
a larger number of patients. The issue of missing data was the major factor 
responsible for the collection of a significantly lower amount of complete data sets 
than anticipated meaning that the total sample ultimately contained about seventy 
fewer data sets than anticipated. Additionally, as described above, several (mostly 
self-report) measures had to be removed from the analysis altogether as they were 
missing for too large a proportion of the final sample. Ultimately, it was possible to 
collect complete pre- and post-treatment data for six variables for a total of 231 
patients and although interesting results were produced, there was potential for a 
much vaster and richer data set to be produced. A sample size of 600 or more 
would have been achievable with more relaxed time constraints and this would have 
had the power to detect small effects with three predictors (Miles and Shevlin, 2001) 
which might have made a difference, particularly where null findings were 
concerned.  
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Conducting research in an NHS ‘real-world’ personality disorder service 
A primary factor contributing to the difficulty in collecting a larger sample of 
complete data related to the challenge of collecting research within a ‘real-world’ 
NHS PD service. This service was set up for the treatment of people with PD and 
does not exist solely as a research unit. Its primary goal is therefore to ensure 
patients receive the best support and treatment for their needs. Any data that can be 
collected during this process is of course extremely valuable, but remains secondary 
to providing effective treatment. The service does, however recognise that in order 
to provide the best treatments, evidence documenting their effectiveness is crucial. 
Additionally, research provides the potential to be able to identify which patients are 
less likely to remain engaged and committed to the therapeutic process as well as 
who is likely to achieve better outcomes. This is vital information that can be used to 
economise resources by allocating patients to treatments they are most likely to 
benefit from and by facilitating improvements for those who are likely to dropout 
from treatment or achieve poor outcomes.   
For this reason, research is valued highly by the service and recent NHS 
initiatives such as Payment by Results (Fairbairn, 2007) highlight the importance for 
therapists at an individual level to ensure that their work can be consistently and 
reliably outcomed.  While clinical settings are the very best option for producing field 
validity in ‘real-world’ services, they also mean that therapists working in the service 
are employed primarily as clinicians, and although they may recognise their skills as 
scientist practitioners who are partly responsible for the evaluation of their 
treatments, they may have felt quite threatened by a research presence analysing 
data which has the ability to assess individual therapists’ outcomes. Of course, this 
highlights strengths but it might also have felt intrusive and anxiety-provoking, 
possibly resulting in some therapists’ lack of cooperation with the research process.  
Unsurprisingly, not all therapists working at the service remained there for 
the duration of the research period and a busy clinical setting meant that multiple 
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researchers and therapists were involved with the project at different times, working 
differently and inconsistently and thus impacting the quality of the data. Additionally, 
busy therapists rightly prioritised writing thorough and useful clinical notes, reports 
and correspondence meaning that scoring measures and interviews was neglected. 
Rating and interpreting data therefore added to the lengthy process of translating 
patient information and measures into useful, usable data. 
As is typical within a population of patients receiving treatment for PD, many 
patients dropped out before the assessment or treatment was complete (Fonagy & 
Bateman, 2006), thus inflating gaps in the data that could not always be reliably 
filled. Attrition was therefore a problem although it is fairly common in longitudinal 
research involving follow-up of patients who entered treatment several months 
previously and is very common in treatment for PD (Barnicot, Katsakou, Marougka & 
Priebe, 2011; Clarkin, Levy, Lenzenweger & Kernberg, 2007; Feigenbaum et al., 
2011). Those who dropped out of treatment made up one quarter of the total sample 
and further exploratory analyses revealed that without their data to provide variation 
for comparisons, many statistical effects were lost, demonstrating that it was 
worthwhile to continue to seek further data even for those patients who dropped out 
prematurely.  
Roth and Fonagy (2005) refer to the laboratory versus naturalistic research 
distinction as research efficacy verses clinical effectiveness. The strengths and 
weaknesses of both methods contribute to great debate in psychotherapy research 
(Fishman, 2000). Despite the aforementioned difficulties encountered when 
conducting research in a ‘live’ clinical setting, the benefits are great. As mentioned, 
this provides the most ecologically valid setting for collecting information about how 
services work, who they treat, how they treat and what the outcomes are. A wealth 
of information exists on a vast number of patients which can be analysed according 
to the service’s interests and hypotheses. In terms of research efficacy, a trial set up 
purely for research purposes may boast tighter control of extraneous variables, 
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fewer incomplete data sets and closer adherence to important ethical procedures 
but would lack field validity. It is this ability to investigate what actually happens 
when treatments are implemented in a ‘real-world’ service exposed to the pitfalls 
and challenges of a tightly-resourced NHS that is most valuable (Binks et al., 2006; 
Feigenbaum et al., 2011). The validity of the data obtained in the current project is 
therefore extremely high and this goes some way towards offsetting the 
aforementioned limitations. 
 
Current issues in PD research 
One of the major factors affecting research and practice within the field of PD 
currently is how PD is classified, and this was evident when conducting the literature 
review and empirical project. In categorising patients with PD for research trials, 
comorbdity within PDs becomes problematic. Twenty per cent of the current study’s 
sample met criteria for more than one PD at baseline assessment. This has been a 
major criticism of the categorical approach to classifying PD (Shedler & Westen, 
2007; Westen & Shedler, 1999) with estimates of PD comorbidity using the 
Structured Clinical Interview for DSM-IV-Axis II (SCID-II; First, Gibbon, Spitzer, 
Williams & Benjamin, 1997) ranging between an additional four to six PD diagnoses 
per patient (Bell & Jackson, 1992; Morey, 1988; Oldham et al., 1992). PD 
comorbidity is important as it has been reported to be associated with poorer 
treatment outcomes (Zanarini, Frankenburg, Hennen & Silk, 2006) and poses 
difficulties when treatment effects need to be analysed separately for different PDs. 
It therefore remains a challenge for future researchers to clarify complex comorbid 
relationships within PD (Links, 2007).   
Very recently, the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-5, American Psychiatric Association, 2013) underwent major changes. The 
new DSM-5 retained the ten subtypes of PD classified under separate categorical 
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definitions, deeming them easiest to use in clinical practice (American Psychiatric 
Association, 2013). However, prior to its publication, much speculation existed as to 
whether or not DSM-5 would switch to a more dimensional or combined 
dimensional/categorical approach where PDs are additionally considered on a 
spectrum or continuum of ‘normal’ behaviour (Rounsaville et al., 2002). This was 
thought to be preferable to a purely categorical approach which uses arguably 
arbitrary cut-off points to define a PD (for example, a diagnosis of BPD may be 
made if someone meets five out of nine of the BPD traits listed in the diagnostic 
criteria, but not if they only meet four). A considerable amount of evidence exists to 
support a more dimensional approach (Clark, 2007; Livesley, 2007; Widiger, 
Livesley & Clark, 2009; Widiger & Trull, 2007) and Morey and Hopwood (2013) 
argue that a dimensional approach has the potential to capture PD traits more 
succinctly using transdiagnostic dimensions that straddle the different possible PD 
subtypes, such as the impulsivity that is seen in both borderline and antisocial PD 
(e.g., Clark 2007; Krueger et al. 2011). A dimensional approach would also go some 
way towards rectifying the aforementioned problems associated with clinical 
comorbidity. 
The DSM-5 (American Psychiatric Association, 2013) also combined DSM-
IV-TR’s (American Psychiatric Association, 2000) Axes I and II into one single Axis, 
grouping PD alongside other clinical syndromes such as anxiety and depression. By 
contrast, this change could be viewed in a positive light, meaning that PD may no 
longer be viewed as markedly different from other mental disorders, meeting the aim 
of the National Institute for Mental Health in England’s (2003) guidance that it need 
not be a diagnosis of exclusion. In time, this may help patients to cope with the 
stigma of their diagnosis. The diagnosis ‘personality disorder’ is not considered to be 
a particularly helpful term (Robertson & Coccia, 2007) and a reduction in the 
negative associated effects of this label may be useful in facilitating patients’ 
compliance with their treatment which the current study has proved leads to 
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improvements in risk and diagnostic outcomes. Moreover, classifying PDs on one 
Axis along with clinical syndromes suggests that they are now considered treatable. 
This is in stark contrast to their previous grouping on the former Axis II along with 
the more untreatable category of ‘mental retardation’. 
 
Implications and recommendations 
The Improving Access to Psychological Therapies for Severe Mental Illness 
initiative (IAPT SMI, 2013) makes this a particularly salient time for research into PD 
treatment outcomes and it is crucial that this research continues to promote its 
importance within the field of mental health. Identifying mechanisms of change, not 
just within DBT and CBT treatment, but also in newer treatments for PD such as 
Mentalization Based Therapy (MBT; Bateman & Fonagy, 2008; Bateman & Fonagy, 
2004) and Schema Therapy (Kellogg & Young, 2006) is vital in educating therapists 
about why their treatments work so that they can target and emphasise those 
mechanisms that have been evidenced to produce the greatest therapeutic change. 
Continued evidence documenting the specific mechanisms that result in the 
effectiveness of CBT, DBT and newer treatments for PD will assist in securing their 
rightful place among the next edition of NICE guidance for PD, attracting the funding 
required to continue providing such valuable services.  
It is recommended in this difficult financial time that future researchers focus 
their attentions on identifying those patients that are less likely to complete 
treatment or to achieve positive outcomes so that more effective alternatives to 
existing interventions can be sought. The current study highlighted factors 
associated with positive treatment outcomes as therapist expertise, good 
attendance and lower levels of substance misuse and this is an important step, not 
only because previous findings were confirmed (e.g. the role of substance misuse in 
treatment outcome) but because novel associations were revealed that warrant 
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further investigation: although it is a limitation that the current study was unable to 
identify patient factors involved in the completion of treatment, it did reveal the role 
of therapist expertise in retaining patients in treatment. Services should offer regular 
training and encourage professional development of therapists to ensure they have 
the chance to improve their skills. Replication of current findings would strengthen 
the case for services to focus resources on promoting these factors in order to be 
more confident of achieving positive outcomes for those most likely to benefit. 
The current project found no significant effect of gender on whether or not 
treatment was completed (although women did attend more sessions than men). 
Gender was also not associated with change in risk outcome, change in number of 
PD diagnoses or change in number of clinical syndrome diagnoses. The current 
National Institute for Health and Clinical Excellence (NICE; 2009) guidance 
recommends DBT for women only and with further evidence documenting the 
effectiveness of both CBT and DBT for men too it is possible that future 
recommendations could be reconsidered to include evidence regarding the 
effectiveness of treatment for both genders.  
 
Conclusions 
It is of course, extremely important for PD treatment services to be based on 
the most up to date evidence, and for this evidence to be widely disseminated for 
maximum advantage. Despite a lower than desired final sample size and difficulties 
with incomplete data meaning that some analyses were not possible, this project 
makes a vital contribution to the current PD evidence base, providing ‘real-world’ 
information on the factors that influence early disengagement with treatment as well 
as the factors that predict successful and unsuccessful clinical outcomes. This 
information means that resources can be most usefully deployed where they are 
most likely to have a positive impact on treatment completion and outcome. 
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